<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">68174</article-id><article-id pub-id-type="doi">10.7554/eLife.68174</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Non-nucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy is associated with lower cell-associated HIV RNA and DNA levels compared to protease inhibitor-based therapy</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-205432"><name><surname>Pasternak</surname><given-names>Alexander O</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4097-4251</contrib-id><email>a.o.pasternak@amsterdamumc.nl</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230024"><name><surname>Vroom</surname><given-names>Jelmer</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230029"><name><surname>Kootstra</surname><given-names>Neeltje A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-9429-7754</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230030"><name><surname>Wit</surname><given-names>Ferdinand WNM</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230031"><name><surname>de Bruin</surname><given-names>Marijn</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230032"><name><surname>De Francesco</surname><given-names>Davide</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230033"><name><surname>Bakker</surname><given-names>Margreet</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230034"><name><surname>Sabin</surname><given-names>Caroline A</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230035"><name><surname>Winston</surname><given-names>Alan</given-names></name><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230036"><name><surname>Prins</surname><given-names>Jan M</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230037"><name><surname>Reiss</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230038"><name><surname>Berkhout</surname><given-names>Ben</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><collab>The Co-morBidity in Relation to Aids (COBRA) Collaboration<contrib-group><contrib contrib-type="author"><name><surname>Reiss</surname><given-names>P</given-names></name><aff><institution>Department of Global Health and Amsterdam Institute for Global Health and Development (AIGHD), Amsterdam UMC, Universiteit van Amsterdam</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Wit</surname><given-names>FWNM</given-names></name><aff><institution>Department of Global Health and Amsterdam Institute for Global Health and Development (AIGHD), Amsterdam UMC, Universiteit van Amsterdam</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Schouten</surname><given-names>J</given-names></name><aff><institution>Department of Global Health and Amsterdam Institute for Global Health and Development (AIGHD), Amsterdam UMC, Universiteit van Amsterdam</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Kooij</surname><given-names>KW</given-names></name><aff><institution>Department of Global Health and Amsterdam Institute for Global Health and Development (AIGHD), Amsterdam UMC, Universiteit van Amsterdam</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>van Zoest</surname><given-names>RA</given-names></name><aff><institution>Department of Global Health and Amsterdam Institute for Global Health and Development (AIGHD), Amsterdam UMC, Universiteit van Amsterdam</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Elsenga</surname><given-names>BC</given-names></name><aff><institution>Department of Global Health and Amsterdam Institute for Global Health and Development (AIGHD), Amsterdam UMC, Universiteit van Amsterdam</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Janssen</surname><given-names>FR</given-names></name><aff><institution>Department of Global Health and Amsterdam Institute for Global Health and Development (AIGHD), Amsterdam UMC, Universiteit van Amsterdam</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Heidenrijk</surname><given-names>M</given-names></name><aff><institution>Department of Global Health and Amsterdam Institute for Global Health and Development (AIGHD), Amsterdam UMC, Universiteit van Amsterdam</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Zikkenheiner</surname><given-names>W</given-names></name><aff><institution>Department of Global Health and Amsterdam Institute for Global Health and Development (AIGHD), Amsterdam UMC, Universiteit van Amsterdam</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>van der Valk</surname><given-names>M</given-names></name><aff><institution>Division of Infectious Diseases, Amsterdam UMC, Universiteit van Amsterdam</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Kootstra</surname><given-names>NA</given-names></name><aff><institution>Department of Experimental Immunology, Amsterdam UMC, Universiteit van Amsterdam</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Booiman</surname><given-names>T</given-names></name><aff><institution>Department of Experimental Immunology, Amsterdam UMC, Universiteit van Amsterdam</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Harskamp-Holwerda</surname><given-names>AM</given-names></name><aff><institution>Department of Experimental Immunology, Amsterdam UMC, Universiteit van Amsterdam</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Maurer</surname><given-names>I</given-names></name><aff><institution>Department of Experimental Immunology, Amsterdam UMC, Universiteit van Amsterdam</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Mangas Ruiz</surname><given-names>MM</given-names></name><aff><institution>Department of Experimental Immunology, Amsterdam UMC, Universiteit van Amsterdam</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Girigorie</surname><given-names>AF</given-names></name><aff><institution>Department of Experimental Immunology, Amsterdam UMC, Universiteit van Amsterdam</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Villaudy</surname><given-names>J</given-names></name><aff><institution>Department of Medical Microbiology, Amsterdam UMC, Universiteit van Amsterdam</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Frankin</surname><given-names>E</given-names></name><aff><institution>Department of Medical Microbiology, Amsterdam UMC, Universiteit van Amsterdam</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Pasternak</surname><given-names>AO</given-names></name><aff><institution>Department of Medical Microbiology, Amsterdam UMC, Universiteit van Amsterdam</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Berkhout</surname><given-names>B</given-names></name><aff><institution>Department of Medical Microbiology, Amsterdam UMC, Universiteit van Amsterdam</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>van der Kuyl</surname><given-names>T</given-names></name><aff><institution>Department of Medical Microbiology, Amsterdam UMC, Universiteit van Amsterdam</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Portegies</surname><given-names>P</given-names></name><aff><institution>Department of Neurology, Amsterdam UMC, Universiteit van Amsterdam</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Schmand</surname><given-names>BA</given-names></name><aff><institution>Department of Neurology, Amsterdam UMC, Universiteit van Amsterdam</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Geurtsen</surname><given-names>GJ</given-names></name><aff><institution>Department of Neurology, Amsterdam UMC, Universiteit van Amsterdam</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>ter Stege</surname><given-names>JA</given-names></name><aff><institution>Department of Neurology, Amsterdam UMC, Universiteit van Amsterdam</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Klein Twennaar</surname><given-names>M</given-names></name><aff><institution>Department of Neurology, Amsterdam UMC, Universiteit van Amsterdam</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Majoie</surname><given-names>CBLM</given-names></name><aff><institution>Department of Radiology, Amsterdam UMC, Universiteit van Amsterdam</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Caan</surname><given-names>MWA</given-names></name><aff><institution>Department of Radiology, Amsterdam UMC, Universiteit van Amsterdam</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Su</surname><given-names>T</given-names></name><aff><institution>Department of Radiology, Amsterdam UMC, Universiteit van Amsterdam</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Weijer</surname><given-names>K</given-names></name><aff><institution>Department of Cell Biology, Amsterdam UMC, Universiteit van Amsterdam</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Bisschop</surname><given-names>PHLT</given-names></name><aff><institution>Division of Endocrinology and Metabolism, Amsterdam UMC, Universiteit van Amsterdam</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Kalsbeek</surname><given-names>A</given-names></name><aff><institution>Department of Experimental Neuroendocrinology, Amsterdam UMC, Universiteit van Amsterdam</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Wezel</surname><given-names>M</given-names></name><aff><institution>Department of Ophthalmology, Amsterdam UMC, Universiteit van Amsterdam</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Visser</surname><given-names>I</given-names></name><aff><institution>Department of Psychiatry, Amsterdam UMC, Universiteit van Amsterdam</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Ruhé</surname><given-names>HG</given-names></name><aff><institution>Department of Psychiatry, Amsterdam UMC, Universiteit van Amsterdam</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Franceschi</surname><given-names>C</given-names></name><aff><institution>Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum Universita di Bologna</institution><addr-line><named-content content-type="city">Bologna</named-content></addr-line><country>Italy</country></aff></contrib><contrib contrib-type="author"><name><surname>Garagnani</surname><given-names>P</given-names></name><aff><institution>Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum Universita di Bologna</institution><addr-line><named-content content-type="city">Bologna</named-content></addr-line><country>Italy</country></aff></contrib><contrib contrib-type="author"><name><surname>Pirazzini</surname><given-names>C</given-names></name><aff><institution>Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum Universita di Bologna</institution><addr-line><named-content content-type="city">Bologna</named-content></addr-line><country>Italy</country></aff></contrib><contrib contrib-type="author"><name><surname>Capri</surname><given-names>M</given-names></name><aff><institution>Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum Universita di Bologna</institution><addr-line><named-content content-type="city">Bologna</named-content></addr-line><country>Italy</country></aff></contrib><contrib contrib-type="author"><name><surname>Dall'Olio</surname><given-names>F</given-names></name><aff><institution>Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum Universita di Bologna</institution><addr-line><named-content content-type="city">Bologna</named-content></addr-line><country>Italy</country></aff></contrib><contrib contrib-type="author"><name><surname>Chiricolo</surname><given-names>M</given-names></name><aff><institution>Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum Universita di Bologna</institution><addr-line><named-content content-type="city">Bologna</named-content></addr-line><country>Italy</country></aff></contrib><contrib contrib-type="author"><name><surname>Salvioli</surname><given-names>S</given-names></name><aff><institution>Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum Universita di Bologna</institution><addr-line><named-content content-type="city">Bologna</named-content></addr-line><country>Italy</country></aff></contrib><contrib contrib-type="author"><name><surname>Hoeijmakers</surname><given-names>J</given-names></name><aff><institution>Department of Genetics, Erasmus Universitair Medisch Centrum Rotterdam</institution><addr-line><named-content content-type="city">Rotterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Pothof</surname><given-names>J</given-names></name><aff><institution>Department of Genetics, Erasmus Universitair Medisch Centrum Rotterdam</institution><addr-line><named-content content-type="city">Rotterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Prins</surname><given-names>M</given-names></name><aff><institution>Cluster of Infectious Diseases, research department, GGD Amsterdam/Public Health Service Amsterdam</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Martens</surname><given-names>M</given-names></name><aff><institution>Cluster of Infectious Diseases, research department, GGD Amsterdam/Public Health Service Amsterdam</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Moll</surname><given-names>S</given-names></name><aff><institution>Cluster of Infectious Diseases, research department, GGD Amsterdam/Public Health Service Amsterdam</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Berkel</surname><given-names>J</given-names></name><aff><institution>Cluster of Infectious Diseases, research department, GGD Amsterdam/Public Health Service Amsterdam</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Totté</surname><given-names>M</given-names></name><aff><institution>Cluster of Infectious Diseases, research department, GGD Amsterdam/Public Health Service Amsterdam</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Kovalev</surname><given-names>S</given-names></name><aff><institution>Cluster of Infectious Diseases, research department, GGD Amsterdam/Public Health Service Amsterdam</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Gisslén</surname><given-names>M</given-names></name><aff><institution>Göteborgs Universitet</institution><addr-line><named-content content-type="city">Gotenburg</named-content></addr-line><country>Sweden</country></aff></contrib><contrib contrib-type="author"><name><surname>Fuchs</surname><given-names>D</given-names></name><aff><institution>Göteborgs Universitet</institution><addr-line><named-content content-type="city">Gotenburg</named-content></addr-line><country>Sweden</country></aff></contrib><contrib contrib-type="author"><name><surname>Zetterberg</surname><given-names>H</given-names></name><aff><institution>Göteborgs Universitet</institution><addr-line><named-content content-type="city">Gotenburg</named-content></addr-line><country>Sweden</country></aff></contrib><contrib contrib-type="author"><name><surname>Winston</surname><given-names>A</given-names></name><aff><institution>Department of Medicine, Division of Infectious Diseases, Imperial College of Science, Technology and Medicine</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Underwood</surname><given-names>J</given-names></name><aff><institution>Department of Medicine, Division of Infectious Diseases, Imperial College of Science, Technology and Medicine</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>McDonald</surname><given-names>L</given-names></name><aff><institution>Department of Medicine, Division of Infectious Diseases, Imperial College of Science, Technology and Medicine</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Stott</surname><given-names>M</given-names></name><aff><institution>Department of Medicine, Division of Infectious Diseases, Imperial College of Science, Technology and Medicine</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Legg</surname><given-names>K</given-names></name><aff><institution>Department of Medicine, Division of Infectious Diseases, Imperial College of Science, Technology and Medicine</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Lovell</surname><given-names>A</given-names></name><aff><institution>Department of Medicine, Division of Infectious Diseases, Imperial College of Science, Technology and Medicine</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Erlwein</surname><given-names>O</given-names></name><aff><institution>Department of Medicine, Division of Infectious Diseases, Imperial College of Science, Technology and Medicine</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Doyle</surname><given-names>N</given-names></name><aff><institution>Department of Medicine, Division of Infectious Diseases, Imperial College of Science, Technology and Medicine</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Kingsley</surname><given-names>C</given-names></name><aff><institution>Department of Medicine, Division of Infectious Diseases, Imperial College of Science, Technology and Medicine</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Sharp</surname><given-names>DJ</given-names></name><aff><institution>Department of Medicine, Division of Brain Sciences, The Computational, Cognitive &amp; Clinical Neuroimaging Laboratory, Imperial College of Science, Technology and Medicine</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Leech</surname><given-names>R</given-names></name><aff><institution>Department of Medicine, Division of Brain Sciences, The Computational, Cognitive &amp; Clinical Neuroimaging Laboratory, Imperial College of Science, Technology and Medicine</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Cole</surname><given-names>JH</given-names></name><aff><institution>Department of Medicine, Division of Brain Sciences, The Computational, Cognitive &amp; Clinical Neuroimaging Laboratory, Imperial College of Science, Technology and Medicine</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Zaheri</surname><given-names>S</given-names></name><aff><institution>Stichting HIV Monitoring</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Hillebregt</surname><given-names>MMJ</given-names></name><aff><institution>Stichting HIV Monitoring</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Ruijs</surname><given-names>YMC</given-names></name><aff><institution>Stichting HIV Monitoring</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Benschop</surname><given-names>DP</given-names></name><aff><institution>Stichting HIV Monitoring</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Burger</surname><given-names>D</given-names></name><aff><institution>Stichting Katholieke Universiteit Nijmegen</institution><addr-line><named-content content-type="city">Nijmegen</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>de Graaff-Teulen</surname><given-names>M</given-names></name><aff><institution>Stichting Katholieke Universiteit Nijmegen</institution><addr-line><named-content content-type="city">Nijmegen</named-content></addr-line><country>Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Guaraldi</surname><given-names>G</given-names></name><aff><institution>Department of Medical and Surgical Sciences for Children &amp; Adults, Università degli studi di Modena e Reggio Emilia</institution><addr-line><named-content content-type="city">Modena</named-content></addr-line><country>Italy</country></aff></contrib><contrib contrib-type="author"><name><surname>Bürkle</surname><given-names>A</given-names></name><aff><institution>Department of Biology, Universität Konstanz</institution><addr-line><named-content content-type="city">Konstanz</named-content></addr-line><country>Germany</country></aff></contrib><contrib contrib-type="author"><name><surname>Sindlinger</surname><given-names>T</given-names></name><aff><institution>Department of Biology, Universität Konstanz</institution><addr-line><named-content content-type="city">Konstanz</named-content></addr-line><country>Germany</country></aff></contrib><contrib contrib-type="author"><name><surname>Moreno-Villanueva</surname><given-names>M</given-names></name><aff><institution>Department of Biology, Universität Konstanz</institution><addr-line><named-content content-type="city">Konstanz</named-content></addr-line><country>Germany</country></aff></contrib><contrib contrib-type="author"><name><surname>Keller</surname><given-names>A</given-names></name><aff><institution>Department of Biology, Universität Konstanz</institution><addr-line><named-content content-type="city">Konstanz</named-content></addr-line><country>Germany</country></aff></contrib><contrib contrib-type="author"><name><surname>Sabin</surname><given-names>C</given-names></name><aff><institution>Research Department of Infection and Population Health, University College London</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>de Francesco</surname><given-names>D</given-names></name><aff><institution>Research Department of Infection and Population Health, University College London</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Libert</surname><given-names>C</given-names></name><aff><institution>Inflammation Research Center, Vlaams Instituut voor Biotechnologie</institution><addr-line><named-content content-type="city">Ghent</named-content></addr-line><country>Belgium</country></aff></contrib><contrib contrib-type="author"><name><surname>Dewaele</surname><given-names>S</given-names></name><aff><institution>Inflammation Research Center, Vlaams Instituut voor Biotechnologie</institution><addr-line><named-content content-type="city">Ghent</named-content></addr-line><country>Belgium</country></aff></contrib></contrib-group></collab><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Amsterdam UMC, University of Amsterdam, Laboratory of Experimental Virology, Department of Medical Microbiology and Infection Prevention</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff><aff id="aff2"><label>2</label><institution>Amsterdam UMC, University of Amsterdam, Laboratory of Viral Immune Pathogenesis, Department of Experimental Immunology</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff><aff id="aff3"><label>3</label><institution>Amsterdam Institute for Global Health and Development</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff><aff id="aff4"><label>4</label><institution>Amsterdam UMC, University of Amsterdam, Department of Global Health, Amsterdam Institute for Infection and Immunity</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff><aff id="aff5"><label>5</label><institution>HIV Monitoring Foundation</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff><aff id="aff6"><label>6</label><institution>Amsterdam UMC, University of Amsterdam, Department of Internal Medicine</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff><aff id="aff7"><label>7</label><institution>Health Psychology Group, Institute of Applied Health Sciences, University of Aberdeen</institution><addr-line><named-content content-type="city">Aberdeen</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff8"><label>8</label><institution>Radboud University Medical Center, Radboud Institute for Health Sciences</institution><addr-line><named-content content-type="city">Nijmegen</named-content></addr-line><country>Netherlands</country></aff><aff id="aff9"><label>9</label><institution>Institute for Global Health, University College London</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff10"><label>10</label><institution>Department of Medicine, Imperial College London</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="senior_editor"><name><surname>Van der Meer</surname><given-names>Jos W</given-names></name><role>Senior Editor</role><aff><institution>Radboud University Medical Centre</institution><country>Netherlands</country></aff></contrib><contrib contrib-type="editor"><name><surname>Overbaugh</surname><given-names>Julie M</given-names></name><role>Reviewing Editor</role><aff><institution>Fred Hutchinson Cancer Research Center</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>13</day><month>08</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e68174</elocation-id><history><date date-type="received" iso-8601-date="2021-03-07"><day>07</day><month>03</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-08-07"><day>07</day><month>08</month><year>2021</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at medRxiv.</event-desc><date date-type="preprint" iso-8601-date="2021-03-26"><day>26</day><month>03</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.03.25.21254129"/></event></pub-history><permissions><copyright-statement>© 2021, Pasternak et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Pasternak et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-68174-v2.pdf"/><abstract><sec id="abs1"><title>Background:</title><p>It remains unclear whether combination antiretroviral therapy (ART) regimens differ in their ability to fully suppress human immunodeficiency virus (HIV) replication. Here, we report the results of two cross-sectional studies that compared levels of cell-associated (CA) HIV markers between individuals receiving suppressive ART containing either a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a protease inhibitor (PI).</p></sec><sec id="abs2"><title>Methods:</title><p>CA HIV unspliced RNA and total HIV DNA were quantified in two cohorts (n = 100, n = 124) of individuals treated with triple ART regimens consisting of two nucleoside reverse transcriptase inhibitors (NRTIs) plus either an NNRTI or a PI. To compare CA HIV RNA and DNA levels between the regimens, we built multivariable models adjusting for age, gender, current and nadir CD4<sup>+</sup> count, plasma viral load zenith, duration of virological suppression, NRTI backbone composition, low-level plasma HIV RNA detectability, and electronically measured adherence to ART.</p></sec><sec id="abs3"><title>Results:</title><p>In both cohorts, levels of CA HIV RNA and DNA strongly correlated (rho = 0.70 and rho = 0.54) and both markers were lower in NNRTI-treated than in PI-treated individuals. In the multivariable analysis, CA RNA in both cohorts remained significantly reduced in NNRTI-treated individuals (p<sub>adj</sub> = 0.02 in both cohorts), with a similar but weaker association between the ART regimen and total HIV DNA (p<sub>adj</sub> = 0.048 and p<sub>adj</sub> = 0.10). No differences in CA HIV RNA or DNA levels were observed between individual NNRTIs or individual PIs, but CA HIV RNA was lower in individuals treated with either nevirapine or efavirenz, compared to PI-treated individuals.</p></sec><sec id="abs4"><title>Conclusions:</title><p>All current classes of antiretroviral drugs only prevent infection of new cells but do not inhibit HIV RNA transcription in long-lived reservoir cells. Therefore, these differences in CA HIV RNA and DNA levels by treatment regimen suggest that NNRTIs are more potent in suppressing HIV residual replication than PIs, which may result in a smaller viral reservoir size.</p></sec><sec id="abs5"><title>Funding:</title><p>This work was supported by ZonMw (09120011910035) and FP7 Health (305522).</p></sec></abstract><kwd-group kwd-group-type="author-keywords"><kwd>HIV</kwd><kwd>virus infection</kwd><kwd>antiviral drugs</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Virus</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001826</institution-id><institution>ZonMw</institution></institution-wrap></funding-source><award-id>09120011910035</award-id><principal-award-recipient><name><surname>Berkhout</surname><given-names>Ben</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100011272</institution-id><institution>FP7 Health</institution></institution-wrap></funding-source><award-id>305522</award-id><principal-award-recipient><name><surname>Reiss</surname><given-names>Peter</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>In two independent cohorts, NNRTI-based cART regimens are associated with significantly lower cell-associated HIV RNA levels than PI-based regimens, suggesting more potent suppression of residual virus replication by NNRTI-based regimens.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>In individuals who are able to adhere to combination antiretroviral therapy (ART), therapy suppresses human immunodeficiency virus (HIV) replication, restores immune function, and prevents the development of acquired immunodeficiency syndrome (AIDS) (<xref ref-type="bibr" rid="bib20">Deeks et al., 2013</xref>). More than 20 different antiretroviral drugs belonging to six main classes are currently approved for clinical use (<xref ref-type="bibr" rid="bib63">Pau and George, 2014</xref>). Depending on the class, these drugs block different steps of the HIV replication cycle, such as reverse transcription, proviral integration, or virus particle maturation. Current ART regimens typically consist of two nucleotide or nucleoside reverse transcriptase inhibitors (NRTIs) and a third drug of another class, for example, a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI), or an integrase strand transfer inhibitor (INSTI).</p><p>Despite the efficient suppression of HIV replication, ART is not curative and has to be sustained lifelong. Persistence of viral reservoirs forms the major obstacle to an HIV cure (<xref ref-type="bibr" rid="bib21">Deeks et al., 2016</xref>). Viral reservoir markers, such as low-level HIV RNA in plasma (residual viremia) and cell-associated (CA) HIV DNA and RNA, can be measured in most treated individuals with plasma HIV RNA suppressed to below the limit of quantification of commercial assays (<xref ref-type="bibr" rid="bib36">Jacobs et al., 2019</xref>; <xref ref-type="bibr" rid="bib62">Pasternak and Berkhout, 2018</xref>; <xref ref-type="bibr" rid="bib58">Pasternak et al., 2013</xref>; <xref ref-type="bibr" rid="bib3">Avettand-Fènoël et al., 2016</xref>; <xref ref-type="bibr" rid="bib68">Sharaf and Li, 2017</xref>). Although HIV latent reservoirs persist primarily by cell longevity and proliferation (<xref ref-type="bibr" rid="bib13">Chomont et al., 2009</xref>; <xref ref-type="bibr" rid="bib45">Maldarelli et al., 2014</xref>; <xref ref-type="bibr" rid="bib73">Wagner et al., 2014</xref>), replenishment of the reservoirs by residual virus replication despite ART has been proposed as an alternative mechanism of HIV persistence (<xref ref-type="bibr" rid="bib14">Chun et al., 2005</xref>; <xref ref-type="bibr" rid="bib44">Lorenzo-Redondo et al., 2016</xref>; <xref ref-type="bibr" rid="bib69">Sigal et al., 2011</xref>). The latter possibility remains a matter of longstanding debate in HIV research field (<xref ref-type="bibr" rid="bib47">Martinez-Picado and Deeks, 2016</xref>). Residual HIV replication can result from insufficient penetration of antiretroviral drugs into tissues and anatomic sanctuaries, causing reduced local drug concentrations in tissue sites (<xref ref-type="bibr" rid="bib23">Estes et al., 2017</xref>; <xref ref-type="bibr" rid="bib26">Fletcher et al., 2014</xref>). However, most (but not all) studies could not demonstrate any measurable virus evolution in peripheral blood and tissues of ART-treated individuals (<xref ref-type="bibr" rid="bib9">Bozzi et al., 2019</xref>; <xref ref-type="bibr" rid="bib72">Van Zyl et al., 2017</xref>; <xref ref-type="bibr" rid="bib38">Joos et al., 2008</xref>). This lack of significant virus evolution on ART is considered one of the strongest arguments against residual HIV replication. On the other hand, a transient increase in episomal HIV DNA has been demonstrated in a number of trials of ART intensification with raltegravir, an INSTI (<xref ref-type="bibr" rid="bib12">Buzón et al., 2010</xref>; <xref ref-type="bibr" rid="bib32">Hatano et al., 2013a</xref>). This accumulation of unintegrated HIV DNA, observed upon blocking integration, revealed ongoing integration events prior to intensification. Because all other antiretroviral drug classes act upstream of INSTIs, this implies that complete rounds of HIV replication (infection of new cells) had been ongoing pre-intensification. However, no decrease in residual HIV viremia could be demonstrated in these and other intensification trials (<xref ref-type="bibr" rid="bib27">Gandhi et al., 2010</xref>; <xref ref-type="bibr" rid="bib49">McMahon et al., 2010</xref>; <xref ref-type="bibr" rid="bib31">Hatano et al., 2011</xref>).</p><p>It is also a matter of debate whether different ART regimens are equally potent in suppressing residual HIV replication. All current antiretroviral drugs act by preventing the infection of new cells and are not expected to inhibit HIV RNA transcription or virus production in the long-lived reservoir cells that were infected prior to ART initiation, or in the progeny of such cells. Therefore, if regimens are equally potent in stopping the infection of new cells, one would not expect to detect a difference in residual viremia or CA RNA levels between ART regimens. Consequently, finding such a difference would suggest that some regimens are more potent in suppressing residual replication than others, arguing that virus suppression is less complete with at least some of the regimens. A number of studies reported lower levels of residual viremia in individuals treated with NNRTI-based, compared to PI-based, ART regimens (<xref ref-type="bibr" rid="bib28">Geretti et al., 2019</xref>; <xref ref-type="bibr" rid="bib15">Darcis et al., 2020a</xref>, reviewed in <xref ref-type="bibr" rid="bib16">Darcis et al., 2020b</xref>). However, to date, few studies have compared levels of CA HIV reservoir markers between different ART regimens (<xref ref-type="bibr" rid="bib50">Nicastri et al., 2008</xref>; <xref ref-type="bibr" rid="bib66">Sarmati et al., 2012</xref>; <xref ref-type="bibr" rid="bib39">Kiselinova et al., 2015</xref>). Here, we cross-sectionally measured CA HIV RNA and DNA in two cohorts of individuals receiving suppressive ART containing two NRTIs and either an NNRTI or a PI.</p></sec><sec id="s2" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th>Reagent type (species) or resource</th><th>Designation</th><th>Source or reference</th><th>Identifiers</th><th>Additional information</th></tr></thead><tbody><tr><td>Biological sample (<italic>Homo sapiens</italic>)</td><td>PBMC samples from HIV-infected individuals</td><td/><td/><td/></tr><tr><td>Commercial assay or kit</td><td>DNA-free DNA Removal Kit</td><td>ThermoFisher Scientific</td><td>Cat# AM1906</td><td/></tr><tr><td>Commercial assay or kit</td><td>Platinum Quantitative PCR SuperMix-UDG</td><td>ThermoFisher Scientific</td><td>Cat# 11730–025</td><td/></tr><tr><td>Commercial assay or kit</td><td>TaqMan β-Actin Detection Reagents</td><td>ThermoFisher Scientific</td><td>Cat# 401846</td><td/></tr><tr><td>Commercial assay or kit</td><td>TaqMan Ribosomal RNA Control Reagents</td><td>ThermoFisher Scientific</td><td>Cat# 4308329</td><td/></tr><tr><td>Chemical compound, drug</td><td>SuperScript III reverse transcriptase</td><td>ThermoFisher Scientific</td><td>Cat# 18080–085</td><td/></tr><tr><td>Chemical compound, drug</td><td>Random primers</td><td>ThermoFisher Scientific</td><td>Cat# 48190–011</td><td/></tr><tr><td>Chemical compound, drug</td><td>RNaseOUT Recombinant Ribonuclease Inhibitor</td><td>ThermoFisher Scientific</td><td>Cat# 10777–019</td><td/></tr><tr><td>Software, algorithm</td><td>Prism 8.3.0</td><td>GraphPad Software</td><td><ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com/">https://www.graphpad.com/</ext-link>; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_002798">SCR_002798</ext-link></td><td/></tr><tr><td>Software, algorithm</td><td>IBM SPSS Statistics (version 25)</td><td>IBM Corporation</td><td><ext-link ext-link-type="uri" xlink:href="https://www.ibm.com/">https://www.ibm.com/</ext-link>; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_019096">SCR_019096</ext-link></td><td/></tr></tbody></table></table-wrap><sec id="s2-1"><title>Study participants</title><p>Participants for the COmorBidity in Relation to AIDS (COBRA) cohort were recruited at two clinical sites in Amsterdam (The Netherlands) and London (UK) from ongoing prospective cohort studies on co-morbidity and aging in HIV, the AGEhIV Cohort Study in Amsterdam (<xref ref-type="bibr" rid="bib67">Schouten et al., 2014</xref>), and the POPPY study in London (<xref ref-type="bibr" rid="bib18">De Francesco et al., 2016</xref>). All participants were required to be at least 45 years of age. The study design and participant characteristics were reported previously (<xref ref-type="bibr" rid="bib19">De Francesco et al., 2018</xref>). Although most COBRA participants had two study visits within 2 years, for the present cross-sectional study, only peripheral blood mononuclear cell (PBMC) samples from the first study visit were used: 63 participants out of 100 were from the Amsterdam sub-cohort and 37 were from the London sub-cohort. The COBRA study was approved by the institutional review board of the Academic Medical Center (Medisch Ethische Toetsingscommissie, reference number NL 30802.018.09) and a UK Research Ethics Committee (REC) (reference number 13/LO/0584 Stanmore, London). All participants provided written informed consent.</p><p>Participants for the Adherence Improving Self-Management Strategy (AIMS) randomized trial were recruited at the HIV outpatient clinic of the Academic Medical Center (Amsterdam). Adherence to ART in this cohort was measured electronically using Medication Event Monitoring System (MEMS)-cap pill bottles (Aardex, Switzerland), which record the moments of bottle opening. Adherence was defined as the percentage of doses taken within a specified time interval (11–13 hr for twice-daily and 22–26 hr for once-daily regimens) during the assessment period. For the present study, the adherence was assessed during 1-month periods that finished less than 20 days before or after the HIV sampling moments. The randomized trial, the results of which were reported previously (<xref ref-type="bibr" rid="bib17">de Bruin et al., 2010</xref>), assessed the impact of a behavioral intervention to increase adherence; therefore, adherence data and PBMC samples were collected at several time points. For the present cross-sectional study, for 93.3% of the participants we used the ‘baseline’ (pre-randomization) PBMC samples and the corresponding adherence assessment data. For the remaining 6.6%, who lacked baseline PBMC samples, samples and data from the subsequent time point were used. The AIMS study was approved by the institutional review board of the Academic Medical Center (protocol number NTR176). The trial is registered at <ext-link ext-link-type="uri" xlink:href="https://www.isrctn.com">https://www.isrctn.com</ext-link> (ISRCTN97730834). All participants provided written informed consent.</p><p>Historical plasma HIV RNA measurements, CD4+ T-cell counts, and treatment data were retrieved from the outpatient medical records. The duration of continuous virological suppression was calculated as the duration of the latest period with undetectable plasma HIV RNA prior to the measurement, allowing isolated ‘blips’ of 50–999 copies/ml. The duration of cumulative suppression was calculated by adding together all such periods of continuous suppression. The duration of the current regimen was calculated as the period during which the participant had been receiving combination ART that included their current NNRTI or PI drug and no other NNRTI or PI.</p></sec><sec id="s2-2"><title>Virological measurements</title><p>Plasma HIV RNA was measured using commercial assays with detection limits of 40 or 50 copies/ml. For CA HIV RNA and total HIV DNA measurements, total nucleic acids were extracted from PBMC using the Boom isolation method (<xref ref-type="bibr" rid="bib8">Boom et al., 1990</xref>). Extracted cellular RNA was treated with DNase (DNA-free kit; Thermo Fisher Scientific) to remove DNA that could interfere with the quantitation and reverse transcribed using random primers and SuperScript III reverse transcriptase (all from Thermo Fisher Scientific). CA HIV unspliced RNA and total HIV DNA were measured using previously described quantitative polymerase chain reaction (qPCR)-based methods (<xref ref-type="bibr" rid="bib55">Pasternak et al., 2008</xref>; <xref ref-type="bibr" rid="bib46">Malnati et al., 2008</xref>). HIV DNA or RNA copy numbers were determined using a 7-point standard curve with a linear range of &gt;5 orders of magnitude that was included in every qPCR run and normalized to the total cellular DNA (by measurement of β-actin DNA) or RNA (by measurement of 18S ribosomal RNA) inputs, respectively, as described previously (<xref ref-type="bibr" rid="bib56">Pasternak et al., 2009</xref>). Non-template control wells were included in every qPCR run and were consistently negative. Total HIV DNA was detectable in 90.0% of participants in the COBRA cohort and in 87.8% in the AIMS cohort. CA HIV RNA was detectable in 86.9% of participants in the COBRA cohort and in 83.7% in the AIMS cohort. Undetectable measurements of CA RNA or DNA were assigned the values corresponding to 50% of the corresponding assay detection limits. The detection limits depended on the amounts of the normalizer (input cellular DNA or RNA), and therefore differed between samples.</p></sec><sec id="s2-3"><title>Statistical analysis</title><p>Variables were compared between NNRTI- and PI-based ART by using Mann-Whitney tests for continuous variables and Fisher’s exact tests or Chi-square tests for categorical variables. Strength of the associations between CA RNA or DNA and other variables was initially assessed by nonparametric Spearman or Mann-Whitney tests, as appropriate, and subsequently by fitting generalized linear models (GLMs) on rank-transformed dependent variables. Binary explanatory variables were included in the models if the representation of the least frequent category was &gt;5%. Therefore, gender and plasma HIV RNA detectability were not included in the model in the COBRA cohort. Similarly, a threshold of 5% was used for inclusion of the NRTI backbone categories in the analysis, resulting in the inclusion of three most frequent categories for each cohort. The most frequent NRTI backbone category was used as a reference category. Explanatory variables that were associated with the dependent variables with a sufficient strength (p &lt; 0.1) in univariable GLM analyses were included in multivariable models. Individual tests are described in the legends to figures and tables. Data were analyzed using Prism 8.3.0 (GraphPad Software) and IBM SPSS Statistics (version 25). All tests were two-sided. p-values &lt;0.05 were considered statistically significant.</p></sec></sec><sec id="s3" sec-type="results"><title>Results</title><sec id="s3-1"><title>CA HIV RNA and DNA in the COBRA cohort</title><p>We measured CA HIV unspliced RNA and total HIV DNA in PBMC samples from participants of the COBRA cohort (<xref ref-type="bibr" rid="bib19">De Francesco et al., 2018</xref>). COBRA is a cohort of HIV-infected individuals aged 45 years or older with sustained HIV suppression on ART recruited from two large European HIV treatment centers in Amsterdam and London. Of the 132 COBRA participants with available PBMC samples, 100 were treated with ART that consisted of two NRTIs plus either one NNRTI (n = 58) or one ritonavir-boosted PI (n = 42) and were included in the analysis. Samples were obtained between April 2011 and December 2014. <xref ref-type="table" rid="table1">Table 1</xref> shows the participant characteristics, grouped according to the treatment regimen. In brief, 95% were male and the median age was 55 years (interquartile range, 51–61 years). 98 participants had undetectable plasma HIV RNA (&lt;50 copies/ml) and two had detectable but low levels (66 and 90 copies/ml). Participants had a median of 118 (62–163) months of cumulative and 99 (47–146) months of continuous virological suppression on ART prior to the measurements and had been treated with their current NNRTI or PI regimen for a median of 69 (38–116) months. The duration of virological suppression on ART and the duration of current regimen prior to the measurements were significantly different between NNRTI- and PI-treated participants (cumulative suppression: median of 137 vs 90 months, respectively, p = 0.004; continuous suppression, median of 118 vs 62 months, respectively, p = 0.001; current regimen: median of 99 vs 48 months, respectively, p &lt; 0.0001).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Characteristics of participants treated with NNRTI- and PI-based ART regimens.</title></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" valign="top">Variable</th><th colspan="3" valign="top">COBRA cohort (n = 100)</th><th colspan="3" valign="top">AIMS cohort (n = 124)</th></tr><tr><th colspan="2" valign="top"/><th valign="top">NNRTI (n = 58)</th><th valign="top">PI (n = 42)</th><th valign="top">p<sup>[i]</sup></th><th valign="top">NNRTI (n = 88)</th><th valign="top">PI (n = 36)</th><th valign="top">p</th></tr></thead><tbody><tr><td colspan="2" valign="top">Age (years)</td><td valign="top">55 (51–61)<sup>[ii]</sup></td><td valign="top">56 (50–62)</td><td valign="top">0.97</td><td valign="top">47 (41–54)</td><td valign="top">44 (39–53)</td><td valign="top">0.23</td></tr><tr><td colspan="2" valign="top">Male gender</td><td valign="top">56 (96.6)</td><td valign="top">39 (92.9)</td><td valign="top">0.65</td><td valign="top">78 (88.6)</td><td valign="top">31 (86.1)</td><td valign="top">0.76</td></tr><tr><td colspan="2" valign="top">Current CD4<sup>+</sup> count (cells/mm<sup>3</sup>)</td><td valign="top">640 (511–796)</td><td valign="top">617 (408–782)</td><td valign="top">0.21</td><td valign="top">550 (368–798)</td><td valign="top">575 (470–745)</td><td valign="top">0.46</td></tr><tr><td colspan="2" valign="top">CD4<sup>+</sup> count nadir (cells/mm<sup>3</sup>)</td><td valign="top">180 (115–253)</td><td valign="top">200 (88–253)</td><td valign="top">0.91</td><td valign="top">160 (83–240)</td><td valign="top">165 (85–220)</td><td valign="top">0.78</td></tr><tr><td colspan="2" valign="top">Plasma HIV RNA zenith (log<sub>10</sub> copies/ml)</td><td valign="top">5.08 (4.71–5.52)</td><td valign="top">5.00 (4.72–5.70)</td><td valign="top">0.84</td><td valign="top">5.21 (4.68–5.62)</td><td valign="top">5.35 (4.96–5.97)</td><td valign="top">0.09</td></tr><tr><td colspan="2" valign="top">Duration of cumulative virological suppression (months)</td><td valign="top">137.0 (93.3–171.3)</td><td valign="top">90.4 (46.5–133.1)</td><td valign="top">0.004</td><td valign="top">55.6 (28.5–90.2)</td><td valign="top">40.2 (11.0–87.5)</td><td valign="top">0.20</td></tr><tr><td colspan="2" valign="top">Duration of continuous virological suppression (months)</td><td valign="top">118.3 (73.6–151.6)</td><td valign="top">62.2 (33.5–118.4)</td><td valign="top">0.001</td><td valign="top">45.4 (25.4–74.3)</td><td valign="top">19.9 (6.2–64.3)</td><td valign="top">0.01</td></tr><tr><td colspan="2" valign="top">Duration of the current NNRTI or PI regimen (months)</td><td valign="top">98.6 (48.4–136.6)</td><td valign="top">48.0 (26.3–68.2)</td><td valign="top">&lt;0.0001</td><td valign="top">39.1 (12.4–59.9)</td><td valign="top">12.5 (7.2–23.6)</td><td valign="top">&lt;0.0001</td></tr><tr><td colspan="2" valign="top">Current plasma HIV RNA &lt;50 copies/ml<sup>[iii]</sup></td><td valign="top">56 (96.6)</td><td valign="top">42 (100.0)</td><td valign="top">0.51</td><td valign="top">80 (90.9)</td><td valign="top">27 (75.0)</td><td valign="top">0.04</td></tr><tr><td colspan="2" valign="top">Adherence to ART (%)<sup>[iv]</sup></td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">89.2 (63.6–100)</td><td valign="top">91.3 (65.5–100)</td><td valign="top">0.55</td></tr><tr><td valign="top">NRTI backbone</td><td valign="top">FTC + TDF<sup>[v]</sup></td><td valign="top">47 (81.0)</td><td valign="top">31 (73.8)</td><td valign="top">0.43</td><td valign="top">8 (9.1)</td><td valign="top">4 (11.1)</td><td valign="top">0.26</td></tr><tr><td valign="top"/><td valign="top">ABC + 3TC</td><td valign="top">4 (6.9)</td><td valign="top">6 (14.3)</td><td valign="top"/><td valign="top">4 (4.5)</td><td valign="top">-</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">3TC + TDF</td><td valign="top">5 (8.6)</td><td valign="top">2 (4.8)</td><td valign="top"/><td valign="top">42 (47.7)</td><td valign="top">21 (58.3)</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">3TC + AZT</td><td valign="top">2 (3.4)</td><td valign="top">1 (2.4)</td><td valign="top"/><td valign="top">26 (29.5)</td><td valign="top">6 (16.7)</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">Other<sup>[vi]</sup></td><td valign="top">-</td><td valign="top">2 (4.8)</td><td valign="top"/><td valign="top">8 (9.1)</td><td valign="top">5 (13.9)</td><td valign="top"/></tr><tr><td valign="top">NNRTI</td><td valign="top">EFV<sup>[vii]</sup></td><td valign="top">28 (48.3)</td><td valign="top">-</td><td valign="top"/><td valign="top">46 (52.3)</td><td valign="top">-</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">NVP</td><td valign="top">26 (44.8)</td><td valign="top">-</td><td valign="top"/><td valign="top">41 (46.6)</td><td valign="top">-</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">Other<sup>[viii]</sup></td><td valign="top">4 (6.9)</td><td valign="top">-</td><td valign="top"/><td valign="top">1 (1.1)</td><td valign="top">-</td><td valign="top"/></tr><tr><td valign="top">PI</td><td valign="top">ATZ/r<sup>[ix]</sup></td><td valign="top">-</td><td valign="top">19 (45.2)</td><td valign="top"/><td valign="top">-</td><td valign="top">22 (61.1)</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">DRV/r</td><td valign="top">-</td><td valign="top">16 (38.1)</td><td valign="top"/><td valign="top">-</td><td valign="top">-</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">LPV/r</td><td valign="top">-</td><td valign="top">3 (7.1)</td><td valign="top"/><td valign="top">-</td><td valign="top">9 (25.0)</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">Other<sup>[x]</sup></td><td valign="top">-</td><td valign="top">4 (9.5)</td><td valign="top"/><td valign="top">-</td><td valign="top">5 (13.9)</td><td valign="top"/></tr></tbody></table><table-wrap-foot><fn><p><sup>[i]</sup>Mann-Whitney tests were used for continuous variables and Fisher’s exact tests or Chi-square tests were used for categorical variables.</p><p><sup>[ii]</sup>Data are medians (interquartile ranges) for continuous variables and numbers (percentages) for discrete variables.</p></fn><fn><p><sup>[iii]</sup>Where detectable, plasma HIV RNA was &lt;400 copies/ml for all patients.</p><p><sup>[iv]</sup>Adherence was measured electronically.</p></fn><fn><p><sup>[v]</sup>NRTIs: FTC, emtricitabine; TDF, tenofovir disoproxil fumarate; ABC, abacavir; 3TC, lamivudine; AZT, zidovudine; D4T, stavudine; DDI, didanosine.</p><p><sup>[vi]</sup>COBRA: ABC+TDF – 1 (PI), ABC+AZT – 1 (PI). AIMS: 3TC+D4T – 3 (NNRTI), 3TC+DDI – 3 (NNRTI) + 2 (PI), D4T+DDI – 1 (NNRTI), DDI+TDF – 1 (NNRTI) + 1 (PI), 3TC+FTC – 1 (PI), AZT+DDI – 1 (PI).</p></fn><fn><p><sup>[vii]</sup>NNRTIs: EFV, efavirenz; ETR, etravirine; NVP, nevirapine; RIL, rilpivirine.</p><p><sup>[viii]</sup>COBRA: ETR – 2, RIL – 2. AIMS: unknown – 1.</p></fn><fn><p><sup>[ix]</sup>PIs: ATZ, atazanavir; DRV, darunavir; FOS, fosamprenavir; LPV, lopinavir; SAQ, saquinavir; IDV, indinavir; /r, ritonavir-boosted PI.</p><p><sup> [x]</sup>COBRA: FOS/r – 3, SAQ/r – 1. AIMS: ATZ – 3, IDV/r – 1, IDV – 1.</p></fn></table-wrap-foot></table-wrap><p>The median CA HIV RNA and total HIV DNA levels in the COBRA cohort were 2.15 (1.58–2.52) log<sub>10</sub> copies/μg total RNA and 2.50 (1.84–2.77) log<sub>10</sub> copies/10<sup>6</sup> PBMC, respectively. <xref ref-type="fig" rid="fig1">Figure 1A</xref> shows correlations of current CD4+ count, CD4+ count nadir, plasma HIV RNA zenith, and duration of continuous virological suppression prior to the measurements, with CA HIV RNA and DNA. Significant correlations with both HIV RNA and DNA were observed for the plasma HIV RNA zenith (rho = 0.22, p = 0.04 and rho = 0.36, p = 0.0004, respectively), but not for any other variable. Duration of cumulative virological suppression and duration of the current regimen were also not associated with either CA HIV RNA or DNA (cumulative suppression: rho = 0.04, p = 0.68 and rho = -0.06, p = 0.60; current regimen: rho = 0.02, p = 0.82 and rho = 0.02, p = 0.87). Furthermore, CA RNA and DNA strongly correlated (rho = 0.70, p &lt; 0.0001) and both markers were lower in NNRTI- than in PI-treated participants (CA RNA: 1.78 (1.58–2.29) vs 2.36 (1.55–2.65) log<sub>10</sub> copies/μg total RNA, p = 0.03; total DNA: 2.46 (1.78–2.64) vs 2.60 (1.93–2.90) log<sub>10</sub> copies/10<sup>6</sup> PBMC, p = 0.07).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Associations of clinical and virological variables, time of virological suppression, and ART regimens (NNRTI-based vs PI-based) with the levels of cell-associated human immunodeficiency virus (HIV) unspliced RNA (US RNA) and total HIV DNA in (<bold>A</bold>) COBRA cohort (n = 100) and (<bold>B</bold>) AIMS cohort (n = 124).</title><p>Units of measurement are US RNA: log<sub>10</sub> copies/μg total RNA, total DNA: log<sub>10</sub> copies/10<sup>6</sup> peripheral blood mononuclear cells (PBMC), CD4 count and CD4 nadir: cells/mm<sup>3</sup>, plasma HIV RNA zenith: log<sub>10</sub> copies/ml. Levels of significance were calculated by Spearman correlation analyses or Mann-Whitney tests, as appropriate. In all correlation graphs, non-nucleoside reverse transcriptase inhibitor (NNRTI)- and protease inhibitor (PI)-treated participants are color-coded (NNRTI - blue, PI - red).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68174-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Effects of duration of cumulative virological suppression and duration of the current regimen on the levels of cell-associated HIV US RNA and total HIV DNA in the AIMS cohort (n = 124).</title><p>Units of measurement are US RNA: log<sub>10</sub> copies/μg total RNA, total DNA: log<sub>10</sub> copies/10<sup>6</sup> PBMC. Levels of significance were calculated by Spearman correlation analyses.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68174-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Differences in duration of continuous and cumulative virological suppression, duration of current regimen, and in adherence to ART between participants with undetectable vs low-level detectable pVL in the AIMS cohort.</title><p>Levels of significance were calculated by Mann-Whitney tests.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68174-fig1-figsupp2-v2.tif"/></fig></fig-group><p>To assess the association of CA HIV RNA and DNA with ART regimens, we built multivariable GLMs, adjusted for a number of demographic and clinical variables (<xref ref-type="fig" rid="fig2">Figure 2A</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a</xref>). Higher plasma HIV RNA zenith and PI-based ART regimen remained significantly associated with higher levels of both CA HIV RNA and DNA in the multivariable analysis (plasma HIV RNA zenith: p<sub>adj </sub>= 0.02 and p<sub>adj </sub>= 0.0001, respectively; ART regimen: p<sub>adj</sub> = 0.02 and p<sub>adj</sub> = 0.048, respectively).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Regression analyses to identify variables associated with cell-associated human immunodeficiency virus (HIV) unspliced (US) RNA and total HIV DNA levels in (<bold>A</bold>) COBRA and (<bold>B</bold>) AIMS cohorts.</title><p>Effect sizes and 95% confidence intervals for US RNA are plotted as log<sub>10</sub> copies per microgram of total cellular RNA and for total DNA as log<sub>10</sub> copies per million peripheral blood mononuclear cells (PBMC). Effect sizes were obtained by fitting generalized linear models. Variables associated with HIV RNA or DNA with p-values &lt;0.1 in the univariable analyses were included in the multivariable analyses.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68174-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Regression analyses to identify variables associated with cell-associated HIV US RNA and total HIV DNA levels in the AIMS cohort, taking into account either (<bold>A</bold>) duration of cumulative virological suppression on ART or (<bold>B</bold>) duration of current ART regimen, prior to the measurements.</title><p>Effect sizes and 95% confidence intervals for US RNA are plotted as log<sub>10</sub> copies per microgram of total cellular RNA and for total DNA as log<sub>10</sub> copies per million PBMC. Effect sizes were obtained by fitting generalized linear models. Variables associated with HIV RNA or DNA with p-values &lt;0.1 in the univariable analyses were included in the multivariable analyses.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68174-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Regression analyses to identify variables associated with cell-associated HIV US RNA and total HIV DNA levels in the AIMS cohort, taking into account both duration of continuous virological suppression on ART and duration of current ART regimen, prior to the measurements.</title><p>Effect sizes and 95% confidence intervals for US RNA are plotted as log<sub>10</sub> copies per microgram of total cellular RNA and for total DNA as log<sub>10</sub> copies per million PBMC. Effect sizes were obtained by fitting generalized linear models. Variables associated with HIV RNA or DNA with p-values &lt;0.1 in the univariable analyses were included in the multivariable analyses.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68174-fig2-figsupp2-v2.tif"/></fig></fig-group></sec><sec id="s3-2"><title>CA HIV RNA and DNA in the AIMS cohort</title><p>Having established an association between CA HIV RNA and DNA and the ART regimen in the COBRA cohort, we sought to validate these observations in another cohort. To this end, we used PBMC samples from participants of the AIMS randomized controlled trial that investigated the effects of a behavioral intervention to increase adherence to ART (<xref ref-type="bibr" rid="bib17">de Bruin et al., 2010</xref>). Participants for this trial with electronically measured adherence had been recruited from HIV-infected individuals on ART visiting the outpatient clinic of the Academic Medical Center (Amsterdam, The Netherlands). Samples were obtained between March 2005 and February 2007. Of the 147 AIMS participants with available PBMC samples, 124 were treated with ART that consisted of two NRTIs plus either one NNRTI (n = 88) or one PI (n = 36) and were included in the analysis. <xref ref-type="table" rid="table1">Table 1</xref> shows the participant characteristics. In brief, 88% were male and the median age was 46 years (interquartile range, 40–54 years). Median adherence to ART was 91% (66–100%). 107 out of 124 participants had undetectable plasma HIV RNA (&lt;50 copies/ml) and 17 had detectable but low levels (range, 52–366 copies/ml). The duration of cumulative (median, 47 (25–88) months) and continuous (40 (17–72) months) virological suppression on ART prior to the measurements, as well as the duration of current NNRTI or PI regimen (median, 26 (10–46) months), was shorter in the AIMS compared to the COBRA cohort. As in the COBRA cohort, the duration of continuous virological suppression on ART prior to the measurements and the duration of the current regimen were significantly different between NNRTI- and PI-treated participants (continuous suppression, medians of 45 vs 20 months, respectively, p = 0.01; current regimen, medians of 39 vs 13 months, respectively, p &lt; 0.0001). In addition, low-level plasma HIV RNA was detectable more frequently in PI-treated than in NNRTI-treated participants (25.0% vs 9.1%, p = 0.04). Other variables, including adherence to ART, did not differ between NNRTI- and PI-treated participants.</p><p>The median CA HIV RNA and total HIV DNA levels in the AIMS cohort were 1.71 (1.25–2.01) log<sub>10</sub> copies/μg total RNA and 2.41 (1.88–2.79) log<sub>10</sub> copies/10<sup>6</sup> PBMC, respectively. <xref ref-type="fig" rid="fig1">Figure 1B</xref> shows correlations of current CD4+ count, CD4+ count nadir, plasma HIV RNA zenith, and duration of continuous virological suppression prior to the measurements with CA HIV RNA and DNA. In contrast to the COBRA cohort, duration of continuous virological suppression was significantly negatively associated with both CA HIV RNA (rho = -0.35, p = 0.0001) and total HIV DNA (rho = -0.25, p = 0.007). Duration of cumulative virological suppression and duration of the current regimen were also significantly negatively associated with both CA HIV RNA (rho = -0.26, p = 0.004 and rho = -0.23, p = 0.01, respectively) and total HIV DNA (rho = -0.20, p = 0.03 and rho = -0.18, p = 0.04, respectively), but these associations were weaker than those of the duration of continuous suppression (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). In addition, current CD4+ count and plasma HIV RNA zenith were negatively (rho = -0.21, p = 0.03) and positively (rho = 0.18, p = 0.049) associated with CA RNA but not with total DNA (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). As in the COBRA cohort, CA RNA and DNA strongly correlated (rho = 0.54, p &lt; 0.0001) and were lower in NNRTI- than in PI-treated participants (CA RNA: 1.60 (1.18–1.99) vs 1.88 (1.51–2.17) log<sub>10</sub> copies/μg total RNA, p = 0.007; total DNA: 2.36 (1.76–2.74) vs 2.57 (2.22–2.98) log<sub>10</sub> copies/10<sup>6</sup> PBMC, p = 0.04).</p><p>Next, we built multivariable GLMs to assess the association of CA HIV RNA and DNA with ART regimens in the AIMS cohort (<xref ref-type="fig" rid="fig2">Figure 2B</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1b</xref>). In addition to the same variables as for the COBRA cohort, these models included gender, plasma HIV RNA detectability, and adherence to ART. Due to co-linearity between the durations of continuous and cumulative virological suppression and the duration of current regimen, only duration of continuous suppression was included in the multivariable analysis, as its associations with HIV RNA and DNA were the strongest among these three measures. The shorter duration of continuous virological suppression prior to the measurements and PI-based ART regimen remained significantly associated with higher levels of CA HIV RNA in the multivariable analysis (duration of suppression: p<sub>adj</sub> = 0.04; ART regimen: p<sub>adj</sub> = 0.02). The shorter duration of continuous suppression was also significantly associated with higher total HIV DNA (p<sub>adj</sub> = 0.03), while the association of ART regimen with HIV DNA did not achieve statistical significance (p<sub>adj</sub> = 0.10). We also built three alternative models, in which either duration of cumulative suppression or the duration of current regimen was included instead of the duration of continuous suppression, or the duration of continuous suppression was included together with the duration of current regimen. The adjusted associations of CA HIV RNA with the ART regimen remained significant in these alternative models (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>, <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>).</p></sec><sec id="s3-3"><title>Sensitivity analysis and associations of individual antiretroviral drugs with CA HIV RNA and DNA in the pooled cohort</title><p>Having observed similar associations of the ART regimen with CA HIV RNA and DNA in both COBRA and AIMS cohorts, we pooled the two cohorts in order to achieve sufficient statistical power to perform a sensitivity analysis and to assess the associations of individual antiretroviral drugs with the levels of CA HIV RNA and DNA. As 11 individuals participated in both cohorts 7 years apart, we excluded the second samples of these individuals from the analysis, bringing the total number of participants in the pooled cohort to 213.</p><p>As expected, both CA HIV RNA and DNA were significantly lower in NNRTI- than in PI-treated participants of the pooled cohort (p = 0.0006 and p = 0.01, respectively) (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). In accordance with this, CA RNA/DNA ratios were not significantly different by ART regimen, although a trend was observed toward lower CA RNA/DNA ratios in NNRTI-treated participants (p = 0.19) (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). To demonstrate that the associations of ART regimens with CA RNA and DNA also hold in those individuals who are stably suppressed on therapy, we performed a sensitivity analysis, limiting the analysis to a subset of participants with undetectable plasma HIV RNA and more than 6 months of continuous virological suppression on ART (n = 178). In this subset, CA HIV RNA remained significantly lower in NNRTI- than in PI-treated participants (p = 0.006), while a trend in the same direction was observed for total HIV DNA (p = 0.05) (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). To confirm that the effects of the ART regimen were independent of the duration of virological suppression, we assigned the participants into four groups according to the duration of continuous suppression (0–1 years, 2–5 years, 6–9 years, and 10 years or more) and compared CA RNA and DNA between NNRTI- and PI-treated individuals in every group separately (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>). In every group, CA RNA levels were lower in NNRTI- than in PI-treated participants, with a similar but weaker effect observed for CA DNA, in complete agreement to the results obtained in the total cohort.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Sensitivity analysis and associations of individual antiretroviral drugs with cell-associated human immunodeficiency virus (HIV) RNA and DNA in the pooled cohort.</title><p>Associations of antiretroviral therapy (ART) regimens (non-nucleoside reverse transcriptase inhibitor (NNRTI)-based vs protease inhibitor (PI)-based) with the levels of cell-associated HIV unspliced RNA (US RNA) and total HIV DNA in either (<bold>A</bold>) the total pooled cohort (n = 213) or (<bold>B</bold>) limiting the analysis to participants with undetectable plasma viral loads (pVLs) and &gt;6 months of virological suppression on ART (n = 178). (<bold>C</bold>) Differences in the levels of US RNA and total HIV DNA between participants treated with ART regimens based on efavirenz (EFV), nevirapine (NVP), or PIs in the total pooled cohort. (<bold>D</bold>) Differences in the levels of US RNA and total HIV DNA between participants treated with ART regimens based on different ritonavir-boosted PIs: atazanavir (ATZ/r), darunavir (DRV/r), or lopinavir (LPV/r) in the total pooled cohort. Units of measurement are US RNA: log<sub>10</sub> copies/μg total RNA, total DNA: log<sub>10</sub> copies/10<sup>6</sup> peripheral blood mononuclear cells (PBMC). Levels of significance were calculated by Mann-Whitney tests or Kruskal-Wallis tests with Dunn’s post-tests, as appropriate. For three-group comparisons, Kruskal-Wallis p-values are shown on top of the graphs and Dunn’s significance levels of pairwise comparisons are shown by asterisks only where significant; **0.001 &lt; p &lt; 0.01; *0.01 &lt; p &lt; 0.05. Participant numbers per regimen are indicated below the graphs.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68174-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Association of ART regimen (NNRTI-based vs PI-based) with the cell-associated HIV US RNA/total HIV DNA ratio in the total pooled cohort (n = 213).</title><p>Level of significance was calculated by Mann-Whitney test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68174-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Associations of ART regimen (NNRTI-based vs PI-based) with the levels of cell-associated HIV US RNA and total HIV DNA in the total pooled cohort.</title><p>Participants were grouped according to the time of continuous virological suppression: 0–1 years, 2–5 years, 6–9 years, and 10 years or more. Units of measurement are US RNA: log<sub>10</sub> copies/μg total RNA, total DNA: log<sub>10</sub> copies/10<sup>6</sup> PBMC.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68174-fig3-figsupp2-v2.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 3.</label><caption><title>Levels of US RNA and total HIV DNA in participants treated with ART regimens based on efavirenz (EFV), nevirapine (NVP), ritonavir-boosted atazanavir (ATZ/r), ritonavir-boosted darunavir (DRV/r), or ritonavir-boosted lopinavir (LPV/r) in the total pooled cohort.</title><p>Units of measurement are US RNA: log<sub>10</sub> copies/μg total RNA, total DNA: log<sub>10</sub> copies/10<sup>6</sup> PBMC. Levels of significance were calculated by Kruskal-Wallis tests. Participant numbers per regimen are indicated below the graphs.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68174-fig3-figsupp3-v2.tif"/></fig></fig-group><p>Next, we assessed the associations of individual drugs with CA HIV RNA and DNA levels (<xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>). As the vast majority of NNRTI-treated participants received either efavirenz or nevirapine, we wondered whether these two drugs had a similar effect on CA RNA and DNA. To this end, we compared the HIV markers between these two drugs and PIs (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). While no difference was observed in CA RNA or total DNA levels between efavirenz- and nevirapine-treated participants, CA RNA was significantly lower in participants treated with either of these drugs compared to PI-treated participants, and a trend in the same direction was observed for total DNA. Finally, no differences were observed in either CA RNA or total DNA levels between three individual ritonavir-boosted PIs that were used by the majority of PI-treated participants (atazanavir, darunavir, and lopinavir) (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). These results demonstrate that the effects of ART regimens on CA RNA and DNA levels were ART class-specific and not drug-specific.</p></sec></sec><sec id="s4" sec-type="discussion"><title>Discussion</title><p>In this study, we demonstrated in two independent cohorts of individuals on suppressive ART that NNRTI-based triple ART regimens are associated with lower levels of CA HIV RNA compared with PI-based regimens. To the best of our knowledge, this is the largest study comparing CA HIV RNA levels between individuals on different ART regimens. Although several studies have compared residual viremia between ART regimens and most have found lower levels in NNRTI-treated than in PI-treated individuals (<xref ref-type="bibr" rid="bib16">Darcis et al., 2020b</xref>), very few groups included other HIV reservoir markers in such comparisons. <xref ref-type="bibr" rid="bib50">Nicastri et al., 2008</xref> reported lower total HIV DNA levels in individuals treated with PI-based regimens and <xref ref-type="bibr" rid="bib66">Sarmati et al., 2012</xref> found no difference in the HIV DNA level by regimen, despite the fact that both studies reported higher residual viremia in PI-treated individuals. <xref ref-type="bibr" rid="bib39">Kiselinova et al., 2015</xref> performed a matched case-control study comparing nevirapine and PIs for residual viremia, total and episomal HIV DNA, and CA HIV RNA and did not find any differences by regimen for any of these markers. Notably, the latter study matched participants for the duration of PI-based or nevirapine-based regimens, but despite this, significant differences were still observed between the nevirapine- and PI-treated groups in total ART duration and duration of plasma HIV RNA suppression. In our study, we reasoned that, in the absence of a priori knowledge of the factors associated with CA HIV levels, such matching, albeit potentially reducing confounding, could introduce a selective bias and the results would therefore not be representative of the total ART-treated population. Instead, we chose for a cohort study design, controlling for a number of factors in the multivariable models.</p><p>Among all demographic and clinical variables, only duration of current regimen and duration of virological suppression were associated with the ART regimen, being longer in NNRTI- than in PI-treated individuals. This can be explained by the fact that while efavirenz and nevirapine, the drugs used by the absolute majority of our NNRTI-treated individuals, were approved for medical use in the late 1990s, modern PIs like atazanavir and darunavir, which were used by most of our PI-treated individuals, were only approved in the mid- or late 2000s. This means that most of the NNRTI-treated individuals in this study started ART, or switched to NNRTIs from the first-generation PIs, earlier than the PI-treated individuals. Because the HIV reservoir generally decays with time on ART (<xref ref-type="bibr" rid="bib70">Siliciano et al., 2003</xref>), this association of duration of suppression with the ART regimen could have potentially confounded the association of the ART regimen with the HIV reservoir measures such as CA RNA and DNA. Indeed, we found that both these HIV markers were negatively associated with the duration of suppression in the AIMS cohort. Interestingly, low-level plasma HIV RNA detectability in that cohort was also negatively associated with the duration of suppression (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>), confirming the results of a previous study (<xref ref-type="bibr" rid="bib15">Darcis et al., 2020a</xref>). However, to our surprise, no association of CA RNA or DNA with the duration of suppression was found in the COBRA cohort. One possible reason for this difference between the two cohorts is that the COBRA participants were on average much longer on ART than the AIMS participants (117.8 vs 47.1 months of cumulative virological suppression, respectively). Decay of the HIV reservoir after ART initiation is multiphasic (<xref ref-type="bibr" rid="bib64">Perelson et al., 1997</xref>; <xref ref-type="bibr" rid="bib7">Blankson et al., 2000</xref>), and while the long-term dynamics of CA RNA has not yet been studied in detail, reports on the dynamics of total HIV DNA and residual plasma viremia have demonstrated that these markers reach a plateau after 5–7 years of treatment (<xref ref-type="bibr" rid="bib52">Palmer et al., 2008</xref>; <xref ref-type="bibr" rid="bib6">Besson et al., 2014</xref>; <xref ref-type="bibr" rid="bib4">Bachmann et al., 2019</xref>), possibly due to clonal expansion of the viral reservoir cells (<xref ref-type="bibr" rid="bib45">Maldarelli et al., 2014</xref>; <xref ref-type="bibr" rid="bib73">Wagner et al., 2014</xref>). If the same applies to CA RNA, then it may be expected that after several years on ART, this reservoir measure will also no longer depend on the time on therapy, something that we indeed observed in the COBRA cohort. Instead, in the COBRA cohort, CA RNA and especially total DNA positively correlated with the plasma HIV RNA zenith, suggesting that even after a decade of ART, the HIV reservoir size is still partly determined by its pre-therapy values. Interestingly, most proviral DNA sequences from ART-treated individuals were recently shown to match circulating HIV variants detected shortly before the start of therapy, suggesting that the HIV reservoir quickly turns over in the untreated infection and that the reservoir that persists on ART has been primarily established at the start of therapy (<xref ref-type="bibr" rid="bib2">Abrahams et al., 2019</xref>; <xref ref-type="bibr" rid="bib10">Brodin et al., 2016</xref>; <xref ref-type="bibr" rid="bib53">Pankau et al., 2020</xref>).</p><p>Another variable that could have confounded the association of the ART regimen with the HIV reservoir measures such as CA HIV RNA is the adherence to ART. Earlier studies have reported lower adherence among individuals treated with older PI-based ART regimens (<xref ref-type="bibr" rid="bib51">O'Connor et al., 2013</xref>). However, we and others have not previously observed a difference in adherence between individuals treated with modern PI- and NNRTI-based regimens (<xref ref-type="bibr" rid="bib59">Pasternak et al., 2015</xref>; <xref ref-type="bibr" rid="bib41">Konstantopoulos et al., 2015</xref>), and in this study, adherence was also not associated with the therapy regimen. We have previously shown that modest non-adherence correlates with longitudinal changes in CA RNA (<xref ref-type="bibr" rid="bib57">Pasternak et al., 2012</xref>). However, no significant association between adherence and CA RNA levels was observed in this study. Adherence was also not associated with low-level plasma HIV RNA detectability (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). The relation between adherence and CA HIV RNA or residual viremia is undoubtedly complex and deserves further research, but it must be noted that while in our previous report the adherence was measured over 1-week periods immediately prior to the HIV sampling moments, in this study we used 1-month adherence measurements taken within 20 days from the sampling moments. Whether short-term adherence is more strongly associated with CA RNA levels or residual viremia remains to be studied.</p><p>Notwithstanding the associations of CA RNA with other factors, in both cohorts, NNRTI-based ART was independently associated with lower CA RNA levels as compared with PI-based ART, as revealed by the multivariable analysis. This analysis revealed very similar effect sizes of the ART regimen on CA RNA in both cohorts, despite the fact that several factors, such as duration of virological suppression and the PI drugs, differed between the cohorts. On average, CA RNA levels were 1.75- to 2-fold lower in the NNRTI-treated participants. This confirms numerous reports that measured lower residual plasma viremia in NNRTI- compared to PI-treated individuals (<xref ref-type="bibr" rid="bib16">Darcis et al., 2020b</xref>). In fact, also in this study, low-level plasma HIV RNA was more frequently detectable in PI-treated than in NNRTI-treated participants, despite no difference in therapy adherence by regimen. Notably, a recent large study of more than 12,000 participants starting ART revealed that PI-treated participants were on average 2.7 times more likely to experience virological failure compared with NNRTI-treated participants (<xref ref-type="bibr" rid="bib22">El Bouzidi et al., 2020</xref>). Moreover, three independent clinical trials of triple ART intensification with raltegravir have previously demonstrated much stronger increases in episomal HIV DNA in PI- compared to NNRTI-treated participants, suggesting that at ‘baseline’, PI-treated individuals had higher levels of residual replication (<xref ref-type="bibr" rid="bib12">Buzón et al., 2010</xref>; <xref ref-type="bibr" rid="bib32">Hatano et al., 2013a</xref>; <xref ref-type="bibr" rid="bib31">Hatano et al., 2011</xref>). Combined, this prior evidence and the results of this study strongly suggest that NNRTIs are more potent in suppressing HIV residual replication than PIs. Constant low-level viral replication, even if it does not cause the development of drug resistance and therapy failure, could exert continuous pressure on the immune system and cause additional morbidity as a result of persistent immune activation, inflammation, and immunosenescence (<xref ref-type="bibr" rid="bib40">Klatt et al., 2013</xref>; <xref ref-type="bibr" rid="bib48">Massanella et al., 2016</xref>). Several studies have reported excess morbidity and mortality rates in infected ART-treated individuals, compared with the general population (<xref ref-type="bibr" rid="bib67">Schouten et al., 2014</xref>; <xref ref-type="bibr" rid="bib29">Guaraldi et al., 2011</xref>; <xref ref-type="bibr" rid="bib43">Lohse et al., 2007</xref>). Although it is still unclear whether this is due to the adverse effects of the antiretroviral drugs or due to the residual HIV activity, our results argue that an effort should be made to ensure HIV replication is maximally suppressed during therapy.</p><p>Interestingly, some NNRTIs, such as rilpivirine, efavirenz, and etravirine, but not nevirapine, can promote selective apoptosis of infected cells by inducing HIV protease-mediated cytotoxicity (<xref ref-type="bibr" rid="bib71">Trinité et al., 2019</xref>). If these NNRTIs are present in cells that are actively producing viral proteins, they may bind to the reverse transcriptase portion of a newly translated Gag-Pol polyprotein and promote its homodimerization, resulting in premature protease activation. This leads to induction of apoptosis and pyroptosis, as well as CARD8 inflammasome activation (<xref ref-type="bibr" rid="bib24">Figueiredo et al., 2006</xref>; <xref ref-type="bibr" rid="bib37">Jochmans et al., 2010</xref>; <xref ref-type="bibr" rid="bib74">Wang et al., 2021</xref>). However, it is very unlikely that such NNRTI effects could contribute to the levels of CA RNA in our cohorts, for two reasons. First, for this mechanism to work, a cell has to express HIV Gag-Pol, and cells that express HIV proteins without ex vivo stimulation are exceedingly rare in ART-treated individuals (<xref ref-type="bibr" rid="bib54">Pardons et al., 2019</xref>). Second, nevirapine, in comparison with other NNRTIs, has no such activity (<xref ref-type="bibr" rid="bib71">Trinité et al., 2019</xref>; <xref ref-type="bibr" rid="bib24">Figueiredo et al., 2006</xref>; <xref ref-type="bibr" rid="bib74">Wang et al., 2021</xref>), but in our study, nevirapine was associated with the same levels of CA RNA as efavirenz, and another study showed even lower levels of residual plasma viremia in nevirapine-treated compared to efavirenz-treated individuals (<xref ref-type="bibr" rid="bib30">Haïm-Boukobza et al., 2011</xref>). This argues against induction of apoptosis of infected cells being a plausible mechanism behind the more pronounced virological suppression by NNRTIs.</p><p>Replenishment of the HIV reservoir by residual virus replication has been proposed as one of the mechanisms of HIV persistence (<xref ref-type="bibr" rid="bib14">Chun et al., 2005</xref>). The association of the ART regimen with total HIV DNA in this study was similar to its association with CA RNA: in both cohorts, levels of total DNA were 1.8-fold lower in the NNRTI-treated participants. This suggests that persistent residual replication in the PI-treated participants may have resulted in a larger viral reservoir. However, this has to be interpreted with caution, as no single marker can at present provide a reliable estimate of the HIV reservoir size (<xref ref-type="bibr" rid="bib68">Sharaf and Li, 2017</xref>). Moreover, different definitions of the HIV reservoir exist. Although total HIV DNA is mostly composed of genetically defective proviruses and thus its measurements overestimate the replication-competent reservoir (<xref ref-type="bibr" rid="bib11">Bruner et al., 2016</xref>), these defective proviruses can be transcribed, translated, and even produce defective viral particles, and therefore can contribute to chronic immune activation and inflammation despite ART (<xref ref-type="bibr" rid="bib65">Pollack et al., 2017</xref>; <xref ref-type="bibr" rid="bib35">Imamichi et al., 2020</xref>; <xref ref-type="bibr" rid="bib34">Imamichi et al., 2016</xref>; <xref ref-type="bibr" rid="bib25">Finzi et al., 2006</xref>). Therefore, it has been proposed to extend the definition of the reservoir to all infected cells that can contribute to the residual HIV pathogenesis (<xref ref-type="bibr" rid="bib3">Avettand-Fènoël et al., 2016</xref>; <xref ref-type="bibr" rid="bib5">Baxter et al., 2018</xref>). Furthermore, both total HIV DNA and CA HIV RNA have been shown to predict the time to viral rebound after ART interruption (<xref ref-type="bibr" rid="bib75">Williams et al., 2014</xref>; <xref ref-type="bibr" rid="bib42">Li et al., 2016</xref>), and we have recently reported that CA HIV RNA was predictive of both time to and magnitude of viral rebound after interruption of temporary ART initiated during primary HIV infection (<xref ref-type="bibr" rid="bib60">Pasternak et al., 2020</xref>). This argues that despite being partially composed of defective proviruses, the transcription-competent reservoir does reflect the replication-competent reservoir (<xref ref-type="bibr" rid="bib5">Baxter et al., 2018</xref>; <xref ref-type="bibr" rid="bib1">Abdel-Mohsen et al., 2020</xref>). In view of our present results, future studies should investigate the effects of different ART regimens on the replication-competent reservoir, as the latter is the main obstacle for the development of an HIV cure (<xref ref-type="bibr" rid="bib61">Pasternak and Berkhout, 2016</xref>). Interestingly, <xref ref-type="bibr" rid="bib42">Li et al., 2016</xref> demonstrated that NNRTI-treated individuals experienced a significantly longer time to viral rebound after ART interruption. This may suggest lower replication-competent reservoirs in individuals treated with NNRTI-based ART regimens, although longer half-lives of NNRTIs, leading to prolonged NNRTI exposure after treatment interruption, provide a plausible additional explanation.</p><p>Our study has some limitations. First, we did not include individuals treated with INSTI-based ART, which is currently recommended as the first-line therapy (<ext-link ext-link-type="uri" xlink:href="https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/11/what-to-start">https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/11/what-to-start</ext-link>), because such individuals were rare (&lt;5%) in the COBRA cohort and absent from the AIMS cohort. Studies in more recent cohorts are necessary to elucidate the differences in CA HIV markers between INSTI-based ART and other regimens. It must be noted that although NNRTI- and PI-based ART regimens are no longer recommended as the first-line therapy in all settings, millions of infected individuals are still treated with these regimens. Thus, our results are relevant for the clinical management of these individuals. Second, although our results provide strong evidence that individuals treated with PI-based ART undergo residual HIV replication, this evidence remains indirect as the direct demonstration of infection of new cells in an ART-treated individual is extremely difficult if not impossible. Therefore, although studies have used various approaches to prove or disprove the existence of residual replication on ART (reviewed in <xref ref-type="bibr" rid="bib58">Pasternak et al., 2013</xref>; <xref ref-type="bibr" rid="bib47">Martinez-Picado and Deeks, 2016</xref>), all these approaches have so far been indirect. Third, although we adjusted our models for a number of clinical parameters, the observational nature of these cohorts means that residual confounding cannot be entirely excluded. For instance, PI-based regimens could have been preferentially prescribed to individuals with a worse viro-immunological profile and/or expected poor therapy adherence, because PIs impose a relatively high genetic barrier to resistance and consequently will be more ‘forgiving’ to non-adherence. However, we did not observe any significant differences by regimen in plasma HIV RNA zenith, current and nadir CD4+ count, or therapy adherence, arguing against such a ‘prescription bias’. In this regard, a clinical trial with a factorial design, in which participants would switch from PI-based to NNRTI-based ART regimens and vice versa, would be important to confirm our findings.</p><p>In summary, here we have demonstrated in two independent cohorts that levels of HIV reservoir markers are lower in individuals treated with NNRTI- as compared to PI-based combination ART. We have previously proposed CA RNA as a sensitive marker of the active HIV reservoir and residual replication (<xref ref-type="bibr" rid="bib58">Pasternak et al., 2013</xref>), a role that is further reinforced by the results of this study. Monitoring of CA RNA levels to detect residual HIV activity despite ART is warranted in order to prevent possible ART complications such as persistent immune activation or therapy failure (<xref ref-type="bibr" rid="bib56">Pasternak et al., 2009</xref>; <xref ref-type="bibr" rid="bib22">El Bouzidi et al., 2020</xref>; <xref ref-type="bibr" rid="bib33">Hatano et al., 2013b</xref>), especially in individuals treated with PI-based regimens.</p></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We are thankful to Gilles Darcis for helpful discussions. We would like to thank the COBRA and AIMS study groups and study participants for helping to establish these cohorts. The COBRA project has received funding from the European Union’s Seventh Framework Programme for research, technological development, and demonstration under grant agreement no. 305522. AOP is supported by the grant no. 09120011910035 from the Dutch Medical Research Council (ZonMw).</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Investigation, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Investigation</p></fn><fn fn-type="con" id="con3"><p>Data curation</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Methodology</p></fn><fn fn-type="con" id="con5"><p>Data curation</p></fn><fn fn-type="con" id="con6"><p>Data curation</p></fn><fn fn-type="con" id="con7"><p>Resources, Data curation</p></fn><fn fn-type="con" id="con8"><p>Formal analysis, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con9"><p>Data curation</p></fn><fn fn-type="con" id="con10"><p>Data curation, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con11"><p>Data curation, Funding acquisition, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Supervision, Funding acquisition, Writing - review and editing</p></fn><fn fn-type="con" id="con13"><p>Funding acquisition</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: The COBRA study was approved by the institutional review board of the Academic Medical Center (Medisch Ethische Toetsingscommissie, reference number NL 30802.018.09) and a UK Research Ethics Committee (REC) (reference number 13/LO/0584 Stanmore, London). All participants provided written informed consent. The AIMS study was approved by the institutional review board of the Academic Medical Center (protocol number NTR176). The trial is registered at https://www.isrctn.com (ISRCTN97730834). All participants provided written informed consent.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Variables associated with cell-associated human immunodeficiency virus (HIV) unspliced (US) RNA and total HIV DNA levels in both cohorts.</title><p>(<bold>a</bold>) Variables associated with cell-associated HIV US RNA and total HIV DNA levels in the COmorBidity in Relation to AIDS (COBRA) cohort. (b) Variables associated with cell-associated HIV US RNA and total HIV DNA levels in the Adherence Improving Self-Management Strategy (AIMS) cohort.</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-68174-supp1-v2.docx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-68174-transrepform-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdel-Mohsen</surname> <given-names>M</given-names></name><name><surname>Richman</surname> <given-names>D</given-names></name><name><surname>Siliciano</surname> <given-names>RF</given-names></name><name><surname>Nussenzweig</surname> <given-names>MC</given-names></name><name><surname>Howell</surname> <given-names>BJ</given-names></name><name><surname>Martinez-Picado</surname> <given-names>J</given-names></name><name><surname>Chomont</surname> <given-names>N</given-names></name><name><surname>Bar</surname> <given-names>KJ</given-names></name><name><surname>Yu</surname> <given-names>XG</given-names></name><name><surname>Lichterfeld</surname> <given-names>M</given-names></name><name><surname>Alcami</surname> <given-names>J</given-names></name><name><surname>Hazuda</surname> <given-names>D</given-names></name><name><surname>Bushman</surname> <given-names>F</given-names></name><name><surname>Siliciano</surname> <given-names>JD</given-names></name><name><surname>Betts</surname> <given-names>MR</given-names></name><name><surname>Spivak</surname> <given-names>AM</given-names></name><name><surname>Planelles</surname> <given-names>V</given-names></name><name><surname>Hahn</surname> <given-names>BH</given-names></name><name><surname>Smith</surname> <given-names>DM</given-names></name><name><surname>Ho</surname> <given-names>YC</given-names></name><name><surname>Buzon</surname> <given-names>MJ</given-names></name><name><surname>Gaebler</surname> <given-names>C</given-names></name><name><surname>Paiardini</surname> <given-names>M</given-names></name><name><surname>Li</surname> <given-names>Q</given-names></name><name><surname>Estes</surname> <given-names>JD</given-names></name><name><surname>Hope</surname> <given-names>TJ</given-names></name><name><surname>Kostman</surname> <given-names>J</given-names></name><name><surname>Mounzer</surname> <given-names>K</given-names></name><name><surname>Caskey</surname> <given-names>M</given-names></name><name><surname>Fox</surname> <given-names>L</given-names></name><name><surname>Frank</surname> <given-names>I</given-names></name><name><surname>Riley</surname> <given-names>JL</given-names></name><name><surname>Tebas</surname> <given-names>P</given-names></name><name><surname>Montaner</surname> <given-names>LJ</given-names></name><collab>BEAT-HIV Delaney Collaboratory to Cure HIV-1 infection</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Recommendations for measuring HIV reservoir size in cure-directed clinical trials</article-title><source>Nature Medicine</source><volume>26</volume><fpage>1339</fpage><lpage>1350</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-1022-1</pub-id><pub-id pub-id-type="pmid">32895573</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abrahams</surname> <given-names>MR</given-names></name><name><surname>Joseph</surname> <given-names>SB</given-names></name><name><surname>Garrett</surname> <given-names>N</given-names></name><name><surname>Tyers</surname> <given-names>L</given-names></name><name><surname>Moeser</surname> <given-names>M</given-names></name><name><surname>Archin</surname> <given-names>N</given-names></name><name><surname>Council</surname> <given-names>OD</given-names></name><name><surname>Matten</surname> <given-names>D</given-names></name><name><surname>Zhou</surname> <given-names>S</given-names></name><name><surname>Doolabh</surname> <given-names>D</given-names></name><name><surname>Anthony</surname> <given-names>C</given-names></name><name><surname>Goonetilleke</surname> <given-names>N</given-names></name><name><surname>Karim</surname> <given-names>SA</given-names></name><name><surname>Margolis</surname> <given-names>DM</given-names></name><name><surname>Pond</surname> <given-names>SK</given-names></name><name><surname>Williamson</surname> <given-names>C</given-names></name><name><surname>Swanstrom</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The replication-competent HIV-1 latent reservoir is primarily established near the time of therapy initiation</article-title><source>Science Translational Medicine</source><volume>11</volume><elocation-id>eaaw5589</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aaw5589</pub-id><pub-id pub-id-type="pmid">31597754</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avettand-Fènoël</surname> <given-names>V</given-names></name><name><surname>Hocqueloux</surname> <given-names>L</given-names></name><name><surname>Ghosn</surname> <given-names>J</given-names></name><name><surname>Cheret</surname> <given-names>A</given-names></name><name><surname>Frange</surname> <given-names>P</given-names></name><name><surname>Melard</surname> <given-names>A</given-names></name><name><surname>Viard</surname> <given-names>JP</given-names></name><name><surname>Rouzioux</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Total HIV-1 DNA, a marker of viral reservoir dynamics with clinical implications</article-title><source>Clinical Microbiology Reviews</source><volume>29</volume><fpage>859</fpage><lpage>880</lpage><pub-id pub-id-type="doi">10.1128/CMR.00015-16</pub-id><pub-id pub-id-type="pmid">27559075</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bachmann</surname> <given-names>N</given-names></name><name><surname>von Siebenthal</surname> <given-names>C</given-names></name><name><surname>Vongrad</surname> <given-names>V</given-names></name><name><surname>Turk</surname> <given-names>T</given-names></name><name><surname>Neumann</surname> <given-names>K</given-names></name><name><surname>Beerenwinkel</surname> <given-names>N</given-names></name><name><surname>Bogojeska</surname> <given-names>J</given-names></name><name><surname>Fellay</surname> <given-names>J</given-names></name><name><surname>Roth</surname> <given-names>V</given-names></name><name><surname>Kok</surname> <given-names>YL</given-names></name><name><surname>Thorball</surname> <given-names>CW</given-names></name><name><surname>Borghesi</surname> <given-names>A</given-names></name><name><surname>Parbhoo</surname> <given-names>S</given-names></name><name><surname>Wieser</surname> <given-names>M</given-names></name><name><surname>Böni</surname> <given-names>J</given-names></name><name><surname>Perreau</surname> <given-names>M</given-names></name><name><surname>Klimkait</surname> <given-names>T</given-names></name><name><surname>Yerly</surname> <given-names>S</given-names></name><name><surname>Battegay</surname> <given-names>M</given-names></name><name><surname>Rauch</surname> <given-names>A</given-names></name><name><surname>Hoffmann</surname> <given-names>M</given-names></name><name><surname>Bernasconi</surname> <given-names>E</given-names></name><name><surname>Cavassini</surname> <given-names>M</given-names></name><name><surname>Kouyos</surname> <given-names>RD</given-names></name><name><surname>Günthard</surname> <given-names>HF</given-names></name><name><surname>Metzner</surname> <given-names>KJ</given-names></name><collab>Swiss HIV Cohort Study</collab></person-group><year iso-8601-date="2019">2019</year><article-title>Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>3193</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-10884-9</pub-id><pub-id pub-id-type="pmid">31324762</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baxter</surname> <given-names>AE</given-names></name><name><surname>O'Doherty</surname> <given-names>U</given-names></name><name><surname>Kaufmann</surname> <given-names>DE</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Beyond the replication-competent HIV reservoir: transcription and translation-competent reservoirs</article-title><source>Retrovirology</source><volume>15</volume><elocation-id>18</elocation-id><pub-id pub-id-type="doi">10.1186/s12977-018-0392-7</pub-id><pub-id pub-id-type="pmid">29394935</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Besson</surname> <given-names>GJ</given-names></name><name><surname>Lalama</surname> <given-names>CM</given-names></name><name><surname>Bosch</surname> <given-names>RJ</given-names></name><name><surname>Gandhi</surname> <given-names>RT</given-names></name><name><surname>Bedison</surname> <given-names>MA</given-names></name><name><surname>Aga</surname> <given-names>E</given-names></name><name><surname>Riddler</surname> <given-names>SA</given-names></name><name><surname>McMahon</surname> <given-names>DK</given-names></name><name><surname>Hong</surname> <given-names>F</given-names></name><name><surname>Mellors</surname> <given-names>JW</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy</article-title><source>Clinical Infectious Diseases</source><volume>59</volume><fpage>1312</fpage><lpage>1321</lpage><pub-id pub-id-type="doi">10.1093/cid/ciu585</pub-id><pub-id pub-id-type="pmid">25073894</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blankson</surname> <given-names>JN</given-names></name><name><surname>Finzi</surname> <given-names>D</given-names></name><name><surname>Pierson</surname> <given-names>TC</given-names></name><name><surname>Sabundayo</surname> <given-names>BP</given-names></name><name><surname>Chadwick</surname> <given-names>K</given-names></name><name><surname>Margolick</surname> <given-names>JB</given-names></name><name><surname>Quinn</surname> <given-names>TC</given-names></name><name><surname>Siliciano</surname> <given-names>RF</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Biphasic decay of latently infected CD4+ T cells in acute human immunodeficiency virus type 1 infection</article-title><source>The Journal of Infectious Diseases</source><volume>182</volume><fpage>1636</fpage><lpage>1642</lpage><pub-id pub-id-type="doi">10.1086/317615</pub-id><pub-id pub-id-type="pmid">11069234</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boom</surname> <given-names>R</given-names></name><name><surname>Sol</surname> <given-names>CJ</given-names></name><name><surname>Salimans</surname> <given-names>MM</given-names></name><name><surname>Jansen</surname> <given-names>CL</given-names></name><name><surname>Wertheim-van Dillen</surname> <given-names>PM</given-names></name><name><surname>van der Noordaa</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Rapid and simple method for purification of nucleic acids</article-title><source>Journal of Clinical Microbiology</source><volume>28</volume><fpage>495</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1128/jcm.28.3.495-503.1990</pub-id><pub-id pub-id-type="pmid">1691208</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bozzi</surname> <given-names>G</given-names></name><name><surname>Simonetti</surname> <given-names>FR</given-names></name><name><surname>Watters</surname> <given-names>SA</given-names></name><name><surname>Anderson</surname> <given-names>EM</given-names></name><name><surname>Gouzoulis</surname> <given-names>M</given-names></name><name><surname>Kearney</surname> <given-names>MF</given-names></name><name><surname>Rote</surname> <given-names>P</given-names></name><name><surname>Lange</surname> <given-names>C</given-names></name><name><surname>Shao</surname> <given-names>W</given-names></name><name><surname>Gorelick</surname> <given-names>R</given-names></name><name><surname>Fullmer</surname> <given-names>B</given-names></name><name><surname>Kumar</surname> <given-names>S</given-names></name><name><surname>Wank</surname> <given-names>S</given-names></name><name><surname>Hewitt</surname> <given-names>S</given-names></name><name><surname>Kleiner</surname> <given-names>DE</given-names></name><name><surname>Hattori</surname> <given-names>J</given-names></name><name><surname>Bale</surname> <given-names>MJ</given-names></name><name><surname>Hill</surname> <given-names>S</given-names></name><name><surname>Bell</surname> <given-names>J</given-names></name><name><surname>Rehm</surname> <given-names>C</given-names></name><name><surname>Grossman</surname> <given-names>Z</given-names></name><name><surname>Yarchoan</surname> <given-names>R</given-names></name><name><surname>Uldrick</surname> <given-names>T</given-names></name><name><surname>Maldarelli</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>No evidence of ongoing HIV replication or compartmentalization in tissues during combination antiretroviral therapy: implications for HIV eradication</article-title><source>Science Advances</source><volume>5</volume><elocation-id>eaav2045</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.aav2045</pub-id><pub-id pub-id-type="pmid">31579817</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brodin</surname> <given-names>J</given-names></name><name><surname>Zanini</surname> <given-names>F</given-names></name><name><surname>Thebo</surname> <given-names>L</given-names></name><name><surname>Lanz</surname> <given-names>C</given-names></name><name><surname>Bratt</surname> <given-names>G</given-names></name><name><surname>Neher</surname> <given-names>RA</given-names></name><name><surname>Albert</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Establishment and stability of the latent HIV-1 DNA reservoir</article-title><source>eLife</source><volume>5</volume><elocation-id>e18889</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.18889</pub-id><pub-id pub-id-type="pmid">27855060</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruner</surname> <given-names>KM</given-names></name><name><surname>Murray</surname> <given-names>AJ</given-names></name><name><surname>Pollack</surname> <given-names>RA</given-names></name><name><surname>Soliman</surname> <given-names>MG</given-names></name><name><surname>Laskey</surname> <given-names>SB</given-names></name><name><surname>Capoferri</surname> <given-names>AA</given-names></name><name><surname>Lai</surname> <given-names>J</given-names></name><name><surname>Strain</surname> <given-names>MC</given-names></name><name><surname>Lada</surname> <given-names>SM</given-names></name><name><surname>Hoh</surname> <given-names>R</given-names></name><name><surname>Ho</surname> <given-names>YC</given-names></name><name><surname>Richman</surname> <given-names>DD</given-names></name><name><surname>Deeks</surname> <given-names>SG</given-names></name><name><surname>Siliciano</surname> <given-names>JD</given-names></name><name><surname>Siliciano</surname> <given-names>RF</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Defective proviruses rapidly accumulate during acute HIV-1 infection</article-title><source>Nature Medicine</source><volume>22</volume><fpage>1043</fpage><lpage>1049</lpage><pub-id pub-id-type="doi">10.1038/nm.4156</pub-id><pub-id pub-id-type="pmid">27500724</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buzón</surname> <given-names>MJ</given-names></name><name><surname>Massanella</surname> <given-names>M</given-names></name><name><surname>Llibre</surname> <given-names>JM</given-names></name><name><surname>Esteve</surname> <given-names>A</given-names></name><name><surname>Dahl</surname> <given-names>V</given-names></name><name><surname>Puertas</surname> <given-names>MC</given-names></name><name><surname>Gatell</surname> <given-names>JM</given-names></name><name><surname>Domingo</surname> <given-names>P</given-names></name><name><surname>Paredes</surname> <given-names>R</given-names></name><name><surname>Sharkey</surname> <given-names>M</given-names></name><name><surname>Palmer</surname> <given-names>S</given-names></name><name><surname>Stevenson</surname> <given-names>M</given-names></name><name><surname>Clotet</surname> <given-names>B</given-names></name><name><surname>Blanco</surname> <given-names>J</given-names></name><name><surname>Martinez-Picado</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects</article-title><source>Nature Medicine</source><volume>16</volume><fpage>460</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1038/nm.2111</pub-id><pub-id pub-id-type="pmid">20228817</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chomont</surname> <given-names>N</given-names></name><name><surname>El-Far</surname> <given-names>M</given-names></name><name><surname>Ancuta</surname> <given-names>P</given-names></name><name><surname>Trautmann</surname> <given-names>L</given-names></name><name><surname>Procopio</surname> <given-names>FA</given-names></name><name><surname>Yassine-Diab</surname> <given-names>B</given-names></name><name><surname>Boucher</surname> <given-names>G</given-names></name><name><surname>Boulassel</surname> <given-names>MR</given-names></name><name><surname>Ghattas</surname> <given-names>G</given-names></name><name><surname>Brenchley</surname> <given-names>JM</given-names></name><name><surname>Schacker</surname> <given-names>TW</given-names></name><name><surname>Hill</surname> <given-names>BJ</given-names></name><name><surname>Douek</surname> <given-names>DC</given-names></name><name><surname>Routy</surname> <given-names>JP</given-names></name><name><surname>Haddad</surname> <given-names>EK</given-names></name><name><surname>Sékaly</surname> <given-names>RP</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation</article-title><source>Nature Medicine</source><volume>15</volume><fpage>893</fpage><lpage>900</lpage><pub-id pub-id-type="doi">10.1038/nm.1972</pub-id><pub-id pub-id-type="pmid">19543283</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chun</surname> <given-names>TW</given-names></name><name><surname>Nickle</surname> <given-names>DC</given-names></name><name><surname>Justement</surname> <given-names>JS</given-names></name><name><surname>Large</surname> <given-names>D</given-names></name><name><surname>Semerjian</surname> <given-names>A</given-names></name><name><surname>Curlin</surname> <given-names>ME</given-names></name><name><surname>O'Shea</surname> <given-names>MA</given-names></name><name><surname>Hallahan</surname> <given-names>CW</given-names></name><name><surname>Daucher</surname> <given-names>M</given-names></name><name><surname>Ward</surname> <given-names>DJ</given-names></name><name><surname>Moir</surname> <given-names>S</given-names></name><name><surname>Mullins</surname> <given-names>JI</given-names></name><name><surname>Kovacs</surname> <given-names>C</given-names></name><name><surname>Fauci</surname> <given-names>AS</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir</article-title><source>Journal of Clinical Investigation</source><volume>115</volume><fpage>3250</fpage><lpage>3255</lpage><pub-id pub-id-type="doi">10.1172/JCI26197</pub-id><pub-id pub-id-type="pmid">16276421</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darcis</surname> <given-names>G</given-names></name><name><surname>Maes</surname> <given-names>N</given-names></name><name><surname>Pasternak</surname> <given-names>AO</given-names></name><name><surname>Sauvage</surname> <given-names>AS</given-names></name><name><surname>Frippiat</surname> <given-names>F</given-names></name><name><surname>Meuris</surname> <given-names>C</given-names></name><name><surname>Uurlings</surname> <given-names>F</given-names></name><name><surname>Lecomte</surname> <given-names>M</given-names></name><name><surname>Léonard</surname> <given-names>P</given-names></name><name><surname>Elmoussaoui</surname> <given-names>M</given-names></name><name><surname>Fombellida</surname> <given-names>K</given-names></name><name><surname>Vaira</surname> <given-names>D</given-names></name><name><surname>Moutschen</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020a</year><article-title>Detectability of HIV residual viremia despite therapy is highly associated with treatment with a protease Inhibitor-Based combination antiretroviral therapy</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>64</volume><elocation-id>e01902-19</elocation-id><pub-id pub-id-type="doi">10.1128/AAC.01902-19</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darcis</surname> <given-names>G</given-names></name><name><surname>Berkhout</surname> <given-names>B</given-names></name><name><surname>Pasternak</surname> <given-names>AO</given-names></name></person-group><year iso-8601-date="2020">2020b</year><article-title>Differences in HIV markers between infected individuals treated with different ART regimens: implications for the persistence of viral reservoirs</article-title><source>Viruses</source><volume>12</volume><elocation-id>489</elocation-id><pub-id pub-id-type="doi">10.3390/v12050489</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Bruin</surname> <given-names>M</given-names></name><name><surname>Hospers</surname> <given-names>HJ</given-names></name><name><surname>van Breukelen</surname> <given-names>GJ</given-names></name><name><surname>Kok</surname> <given-names>G</given-names></name><name><surname>Koevoets</surname> <given-names>WM</given-names></name><name><surname>Prins</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Electronic monitoring-based counseling to enhance adherence among HIV-infected patients: a randomized controlled trial</article-title><source>Health Psychology</source><volume>29</volume><fpage>421</fpage><lpage>428</lpage><pub-id pub-id-type="doi">10.1037/a0020335</pub-id><pub-id pub-id-type="pmid">20658830</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Francesco</surname> <given-names>D</given-names></name><name><surname>Underwood</surname> <given-names>J</given-names></name><name><surname>Post</surname> <given-names>FA</given-names></name><name><surname>Vera</surname> <given-names>JH</given-names></name><name><surname>Williams</surname> <given-names>I</given-names></name><name><surname>Boffito</surname> <given-names>M</given-names></name><name><surname>Sachikonye</surname> <given-names>M</given-names></name><name><surname>Anderson</surname> <given-names>J</given-names></name><name><surname>Mallon</surname> <given-names>PW</given-names></name><name><surname>Winston</surname> <given-names>A</given-names></name><name><surname>Sabin</surname> <given-names>CA</given-names></name><collab>POPPY study group</collab></person-group><year iso-8601-date="2016">2016</year><article-title>Defining cognitive impairment in people-living-with-HIV: the POPPY study</article-title><source>BMC Infectious Diseases</source><volume>16</volume><elocation-id>617</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-016-1970-8</pub-id><pub-id pub-id-type="pmid">27793128</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Francesco</surname> <given-names>D</given-names></name><name><surname>Wit</surname> <given-names>FW</given-names></name><name><surname>Cole</surname> <given-names>JH</given-names></name><name><surname>Kootstra</surname> <given-names>NA</given-names></name><name><surname>Winston</surname> <given-names>A</given-names></name><name><surname>Sabin</surname> <given-names>CA</given-names></name><name><surname>Underwood</surname> <given-names>J</given-names></name><name><surname>van Zoest</surname> <given-names>RA</given-names></name><name><surname>Schouten</surname> <given-names>J</given-names></name><name><surname>Kooij</surname> <given-names>KW</given-names></name><name><surname>Prins</surname> <given-names>M</given-names></name><name><surname>Guaraldi</surname> <given-names>G</given-names></name><name><surname>Caan</surname> <given-names>MWA</given-names></name><name><surname>Burger</surname> <given-names>D</given-names></name><name><surname>Franceschi</surname> <given-names>C</given-names></name><name><surname>Libert</surname> <given-names>C</given-names></name><name><surname>Bürkle</surname> <given-names>A</given-names></name><name><surname>Reiss</surname> <given-names>P</given-names></name><collab>COmorBidity in Relation to AIDS (COBRA) collaboration</collab></person-group><year iso-8601-date="2018">2018</year><article-title>The 'COmorBidity in Relation to AIDS' (COBRA) cohort: Design, methods and participant characteristics</article-title><source>PLOS ONE</source><volume>13</volume><elocation-id>e0191791</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0191791</pub-id><pub-id pub-id-type="pmid">29596425</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deeks</surname> <given-names>SG</given-names></name><name><surname>Lewin</surname> <given-names>SR</given-names></name><name><surname>Havlir</surname> <given-names>DV</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The end of AIDS: hiv infection as a chronic disease</article-title><source>The Lancet</source><volume>382</volume><fpage>1525</fpage><lpage>1533</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(13)61809-7</pub-id><pub-id pub-id-type="pmid">24152939</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deeks</surname> <given-names>SG</given-names></name><name><surname>Lewin</surname> <given-names>SR</given-names></name><name><surname>Ross</surname> <given-names>AL</given-names></name><name><surname>Ananworanich</surname> <given-names>J</given-names></name><name><surname>Benkirane</surname> <given-names>M</given-names></name><name><surname>Cannon</surname> <given-names>P</given-names></name><name><surname>Chomont</surname> <given-names>N</given-names></name><name><surname>Douek</surname> <given-names>D</given-names></name><name><surname>Lifson</surname> <given-names>JD</given-names></name><name><surname>Lo</surname> <given-names>Y-R</given-names></name><name><surname>Kuritzkes</surname> <given-names>D</given-names></name><name><surname>Margolis</surname> <given-names>D</given-names></name><name><surname>Mellors</surname> <given-names>J</given-names></name><name><surname>Persaud</surname> <given-names>D</given-names></name><name><surname>Tucker</surname> <given-names>JD</given-names></name><name><surname>Barre-Sinoussi</surname> <given-names>F</given-names></name><name><surname>Alter</surname> <given-names>G</given-names></name><name><surname>Auerbach</surname> <given-names>J</given-names></name><name><surname>Autran</surname> <given-names>B</given-names></name><name><surname>Barouch</surname> <given-names>DH</given-names></name><name><surname>Behrens</surname> <given-names>G</given-names></name><name><surname>Cavazzana</surname> <given-names>M</given-names></name><name><surname>Chen</surname> <given-names>Z</given-names></name><name><surname>Cohen</surname> <given-names>EA</given-names></name><name><surname>Corbelli</surname> <given-names>GM</given-names></name><name><surname>Eholié</surname> <given-names>S</given-names></name><name><surname>Eyal</surname> <given-names>N</given-names></name><name><surname>Fidler</surname> <given-names>S</given-names></name><name><surname>Garcia</surname> <given-names>L</given-names></name><name><surname>Grossman</surname> <given-names>C</given-names></name><name><surname>Henderson</surname> <given-names>G</given-names></name><name><surname>Henrich</surname> <given-names>TJ</given-names></name><name><surname>Jefferys</surname> <given-names>R</given-names></name><name><surname>Kiem</surname> <given-names>H-P</given-names></name><name><surname>McCune</surname> <given-names>J</given-names></name><name><surname>Moodley</surname> <given-names>K</given-names></name><name><surname>Newman</surname> <given-names>PA</given-names></name><name><surname>Nijhuis</surname> <given-names>M</given-names></name><name><surname>Nsubuga</surname> <given-names>MS</given-names></name><name><surname>Ott</surname> <given-names>M</given-names></name><name><surname>Palmer</surname> <given-names>S</given-names></name><name><surname>Richman</surname> <given-names>D</given-names></name><name><surname>Saez-Cirion</surname> <given-names>A</given-names></name><name><surname>Sharp</surname> <given-names>M</given-names></name><name><surname>Siliciano</surname> <given-names>J</given-names></name><name><surname>Silvestri</surname> <given-names>G</given-names></name><name><surname>Singh</surname> <given-names>J</given-names></name><name><surname>Spire</surname> <given-names>B</given-names></name><name><surname>Taylor</surname> <given-names>J</given-names></name><name><surname>Tolstrup</surname> <given-names>M</given-names></name><name><surname>Valente</surname> <given-names>S</given-names></name><name><surname>van Lunzen</surname> <given-names>J</given-names></name><name><surname>Walensky</surname> <given-names>R</given-names></name><name><surname>Wilson</surname> <given-names>I</given-names></name><name><surname>Zack</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>International AIDS society global scientific strategy: towards an HIV cure 2016</article-title><source>Nature Medicine</source><volume>22</volume><fpage>839</fpage><lpage>850</lpage><pub-id pub-id-type="doi">10.1038/nm.4108</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El Bouzidi</surname> <given-names>K</given-names></name><name><surname>Jose</surname> <given-names>S</given-names></name><name><surname>Phillips</surname> <given-names>AN</given-names></name><name><surname>Pozniak</surname> <given-names>A</given-names></name><name><surname>Ustianowski</surname> <given-names>A</given-names></name><name><surname>Gompels</surname> <given-names>M</given-names></name><name><surname>Winston</surname> <given-names>A</given-names></name><name><surname>Schaap</surname> <given-names>A</given-names></name><name><surname>Dunn</surname> <given-names>DT</given-names></name><name><surname>Sabin</surname> <given-names>CA</given-names></name><collab>UK CHIC Study</collab></person-group><year iso-8601-date="2020">2020</year><article-title>First-line HIV treatment outcomes following the introduction of integrase inhibitors in UK guidelines</article-title><source>Aids</source><volume>34</volume><fpage>1823</fpage><lpage>1831</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000002603</pub-id><pub-id pub-id-type="pmid">32516283</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Estes</surname> <given-names>JD</given-names></name><name><surname>Kityo</surname> <given-names>C</given-names></name><name><surname>Ssali</surname> <given-names>F</given-names></name><name><surname>Swainson</surname> <given-names>L</given-names></name><name><surname>Makamdop</surname> <given-names>KN</given-names></name><name><surname>Del Prete</surname> <given-names>GQ</given-names></name><name><surname>Deeks</surname> <given-names>SG</given-names></name><name><surname>Luciw</surname> <given-names>PA</given-names></name><name><surname>Chipman</surname> <given-names>JG</given-names></name><name><surname>Beilman</surname> <given-names>GJ</given-names></name><name><surname>Hoskuldsson</surname> <given-names>T</given-names></name><name><surname>Khoruts</surname> <given-names>A</given-names></name><name><surname>Anderson</surname> <given-names>J</given-names></name><name><surname>Deleage</surname> <given-names>C</given-names></name><name><surname>Jasurda</surname> <given-names>J</given-names></name><name><surname>Schmidt</surname> <given-names>TE</given-names></name><name><surname>Hafertepe</surname> <given-names>M</given-names></name><name><surname>Callisto</surname> <given-names>SP</given-names></name><name><surname>Pearson</surname> <given-names>H</given-names></name><name><surname>Reimann</surname> <given-names>T</given-names></name><name><surname>Schuster</surname> <given-names>J</given-names></name><name><surname>Schoephoerster</surname> <given-names>J</given-names></name><name><surname>Southern</surname> <given-names>P</given-names></name><name><surname>Perkey</surname> <given-names>K</given-names></name><name><surname>Shang</surname> <given-names>L</given-names></name><name><surname>Wietgrefe</surname> <given-names>SW</given-names></name><name><surname>Fletcher</surname> <given-names>CV</given-names></name><name><surname>Lifson</surname> <given-names>JD</given-names></name><name><surname>Douek</surname> <given-names>DC</given-names></name><name><surname>McCune</surname> <given-names>JM</given-names></name><name><surname>Haase</surname> <given-names>AT</given-names></name><name><surname>Schacker</surname> <given-names>TW</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Defining total-body AIDS-virus burden with implications for curative strategies</article-title><source>Nature Medicine</source><volume>23</volume><fpage>1271</fpage><lpage>1276</lpage><pub-id pub-id-type="doi">10.1038/nm.4411</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Figueiredo</surname> <given-names>A</given-names></name><name><surname>Moore</surname> <given-names>KL</given-names></name><name><surname>Mak</surname> <given-names>J</given-names></name><name><surname>Sluis-Cremer</surname> <given-names>N</given-names></name><name><surname>de Bethune</surname> <given-names>MP</given-names></name><name><surname>Tachedjian</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol</article-title><source>PLOS Pathogens</source><volume>2</volume><elocation-id>e119</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.0020119</pub-id><pub-id pub-id-type="pmid">17096588</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finzi</surname> <given-names>D</given-names></name><name><surname>Plaeger</surname> <given-names>SF</given-names></name><name><surname>Dieffenbach</surname> <given-names>CW</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Defective virus drives human immunodeficiency virus infection, persistence, and pathogenesis</article-title><source>Clinical and Vaccine Immunology</source><volume>13</volume><fpage>715</fpage><lpage>721</lpage><pub-id pub-id-type="doi">10.1128/CVI.00052-06</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fletcher</surname> <given-names>CV</given-names></name><name><surname>Staskus</surname> <given-names>K</given-names></name><name><surname>Wietgrefe</surname> <given-names>SW</given-names></name><name><surname>Rothenberger</surname> <given-names>M</given-names></name><name><surname>Reilly</surname> <given-names>C</given-names></name><name><surname>Chipman</surname> <given-names>JG</given-names></name><name><surname>Beilman</surname> <given-names>GJ</given-names></name><name><surname>Khoruts</surname> <given-names>A</given-names></name><name><surname>Thorkelson</surname> <given-names>A</given-names></name><name><surname>Schmidt</surname> <given-names>TE</given-names></name><name><surname>Anderson</surname> <given-names>J</given-names></name><name><surname>Perkey</surname> <given-names>K</given-names></name><name><surname>Stevenson</surname> <given-names>M</given-names></name><name><surname>Perelson</surname> <given-names>AS</given-names></name><name><surname>Douek</surname> <given-names>DC</given-names></name><name><surname>Haase</surname> <given-names>AT</given-names></name><name><surname>Schacker</surname> <given-names>TW</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues</article-title><source>PNAS</source><volume>111</volume><fpage>2307</fpage><lpage>2312</lpage><pub-id pub-id-type="doi">10.1073/pnas.1318249111</pub-id><pub-id pub-id-type="pmid">24469825</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gandhi</surname> <given-names>RT</given-names></name><name><surname>Zheng</surname> <given-names>L</given-names></name><name><surname>Bosch</surname> <given-names>RJ</given-names></name><name><surname>Chan</surname> <given-names>ES</given-names></name><name><surname>Margolis</surname> <given-names>DM</given-names></name><name><surname>Read</surname> <given-names>S</given-names></name><name><surname>Kallungal</surname> <given-names>B</given-names></name><name><surname>Palmer</surname> <given-names>S</given-names></name><name><surname>Medvik</surname> <given-names>K</given-names></name><name><surname>Lederman</surname> <given-names>MM</given-names></name><name><surname>Alatrakchi</surname> <given-names>N</given-names></name><name><surname>Jacobson</surname> <given-names>JM</given-names></name><name><surname>Wiegand</surname> <given-names>A</given-names></name><name><surname>Kearney</surname> <given-names>M</given-names></name><name><surname>Coffin</surname> <given-names>JM</given-names></name><name><surname>Mellors</surname> <given-names>JW</given-names></name><name><surname>Eron</surname> <given-names>JJ</given-names></name><collab>AIDS Clinical Trials Group A5244 team</collab></person-group><year iso-8601-date="2010">2010</year><article-title>The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial</article-title><source>PLOS Medicine</source><volume>7</volume><elocation-id>e1000321</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pmed.1000321</pub-id><pub-id pub-id-type="pmid">20711481</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geretti</surname> <given-names>AM</given-names></name><name><surname>White</surname> <given-names>E</given-names></name><name><surname>Orkin</surname> <given-names>C</given-names></name><name><surname>Tostevin</surname> <given-names>A</given-names></name><name><surname>Tilston</surname> <given-names>P</given-names></name><name><surname>Chadwick</surname> <given-names>D</given-names></name><name><surname>Leen</surname> <given-names>C</given-names></name><name><surname>Sabin</surname> <given-names>C</given-names></name><name><surname>Dunn</surname> <given-names>DT</given-names></name><collab>UK HIV Drug Resistance Database and UK CHIC Study</collab></person-group><year iso-8601-date="2019">2019</year><article-title>Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance</article-title><source>Journal of Antimicrobial Chemotherapy</source><volume>74</volume><fpage>746</fpage><lpage>753</lpage><pub-id pub-id-type="doi">10.1093/jac/dky468</pub-id><pub-id pub-id-type="pmid">30544247</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guaraldi</surname> <given-names>G</given-names></name><name><surname>Orlando</surname> <given-names>G</given-names></name><name><surname>Zona</surname> <given-names>S</given-names></name><name><surname>Menozzi</surname> <given-names>M</given-names></name><name><surname>Carli</surname> <given-names>F</given-names></name><name><surname>Garlassi</surname> <given-names>E</given-names></name><name><surname>Berti</surname> <given-names>A</given-names></name><name><surname>Rossi</surname> <given-names>E</given-names></name><name><surname>Roverato</surname> <given-names>A</given-names></name><name><surname>Palella</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Premature age-related comorbidities among HIV-infected persons compared with the general population</article-title><source>Clinical Infectious Diseases</source><volume>53</volume><fpage>1120</fpage><lpage>1126</lpage><pub-id pub-id-type="doi">10.1093/cid/cir627</pub-id><pub-id pub-id-type="pmid">21998278</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haïm-Boukobza</surname> <given-names>S</given-names></name><name><surname>Morand-Joubert</surname> <given-names>L</given-names></name><name><surname>Flandre</surname> <given-names>P</given-names></name><name><surname>Valin</surname> <given-names>N</given-names></name><name><surname>Fourati</surname> <given-names>S</given-names></name><name><surname>Sayon</surname> <given-names>S</given-names></name><name><surname>Lavignon</surname> <given-names>M</given-names></name><name><surname>Simon</surname> <given-names>A</given-names></name><name><surname>Girard</surname> <given-names>PM</given-names></name><name><surname>Katlama</surname> <given-names>C</given-names></name><name><surname>Calvez</surname> <given-names>V</given-names></name><name><surname>Marcelin</surname> <given-names>AG</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml</article-title><source>Aids</source><volume>25</volume><fpage>341</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1097/QAD.0b013e3283427de3</pub-id><pub-id pub-id-type="pmid">21157295</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatano</surname> <given-names>H</given-names></name><name><surname>Hayes</surname> <given-names>TL</given-names></name><name><surname>Dahl</surname> <given-names>V</given-names></name><name><surname>Sinclair</surname> <given-names>E</given-names></name><name><surname>Lee</surname> <given-names>TH</given-names></name><name><surname>Hoh</surname> <given-names>R</given-names></name><name><surname>Lampiris</surname> <given-names>H</given-names></name><name><surname>Hunt</surname> <given-names>PW</given-names></name><name><surname>Palmer</surname> <given-names>S</given-names></name><name><surname>McCune</surname> <given-names>JM</given-names></name><name><surname>Martin</surname> <given-names>JN</given-names></name><name><surname>Busch</surname> <given-names>MP</given-names></name><name><surname>Shacklett</surname> <given-names>BL</given-names></name><name><surname>Deeks</surname> <given-names>SG</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response</article-title><source>The Journal of Infectious Diseases</source><volume>203</volume><fpage>960</fpage><lpage>968</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiq138</pub-id><pub-id pub-id-type="pmid">21402547</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatano</surname> <given-names>H</given-names></name><name><surname>Strain</surname> <given-names>MC</given-names></name><name><surname>Scherzer</surname> <given-names>R</given-names></name><name><surname>Bacchetti</surname> <given-names>P</given-names></name><name><surname>Wentworth</surname> <given-names>D</given-names></name><name><surname>Hoh</surname> <given-names>R</given-names></name><name><surname>Martin</surname> <given-names>JN</given-names></name><name><surname>McCune</surname> <given-names>JM</given-names></name><name><surname>Neaton</surname> <given-names>JD</given-names></name><name><surname>Tracy</surname> <given-names>RP</given-names></name><name><surname>Hsue</surname> <given-names>PY</given-names></name><name><surname>Richman</surname> <given-names>DD</given-names></name><name><surname>Deeks</surname> <given-names>SG</given-names></name></person-group><year iso-8601-date="2013">2013a</year><article-title>Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial</article-title><source>The Journal of Infectious Diseases</source><volume>208</volume><fpage>1436</fpage><lpage>1442</lpage><pub-id pub-id-type="doi">10.1093/infdis/jit453</pub-id><pub-id pub-id-type="pmid">23975885</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatano</surname> <given-names>H</given-names></name><name><surname>Jain</surname> <given-names>V</given-names></name><name><surname>Hunt</surname> <given-names>PW</given-names></name><name><surname>Lee</surname> <given-names>TH</given-names></name><name><surname>Sinclair</surname> <given-names>E</given-names></name><name><surname>Do</surname> <given-names>TD</given-names></name><name><surname>Hoh</surname> <given-names>R</given-names></name><name><surname>Martin</surname> <given-names>JN</given-names></name><name><surname>McCune</surname> <given-names>JM</given-names></name><name><surname>Hecht</surname> <given-names>F</given-names></name><name><surname>Busch</surname> <given-names>MP</given-names></name><name><surname>Deeks</surname> <given-names>SG</given-names></name></person-group><year iso-8601-date="2013">2013b</year><article-title>Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells</article-title><source>The Journal of Infectious Diseases</source><volume>208</volume><fpage>50</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1093/infdis/jis630</pub-id><pub-id pub-id-type="pmid">23089590</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imamichi</surname> <given-names>H</given-names></name><name><surname>Dewar</surname> <given-names>RL</given-names></name><name><surname>Adelsberger</surname> <given-names>JW</given-names></name><name><surname>Rehm</surname> <given-names>CA</given-names></name><name><surname>O'Doherty</surname> <given-names>U</given-names></name><name><surname>Paxinos</surname> <given-names>EE</given-names></name><name><surname>Fauci</surname> <given-names>AS</given-names></name><name><surname>Lane</surname> <given-names>HC</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Defective HIV-1 proviruses produce novel protein-coding RNA species in HIV-infected patients on combination antiretroviral therapy</article-title><source>PNAS</source><volume>113</volume><fpage>8783</fpage><lpage>8788</lpage><pub-id pub-id-type="doi">10.1073/pnas.1609057113</pub-id><pub-id pub-id-type="pmid">27432972</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imamichi</surname> <given-names>H</given-names></name><name><surname>Smith</surname> <given-names>M</given-names></name><name><surname>Adelsberger</surname> <given-names>JW</given-names></name><name><surname>Izumi</surname> <given-names>T</given-names></name><name><surname>Scrimieri</surname> <given-names>F</given-names></name><name><surname>Sherman</surname> <given-names>BT</given-names></name><name><surname>Rehm</surname> <given-names>CA</given-names></name><name><surname>Imamichi</surname> <given-names>T</given-names></name><name><surname>Pau</surname> <given-names>A</given-names></name><name><surname>Catalfamo</surname> <given-names>M</given-names></name><name><surname>Fauci</surname> <given-names>AS</given-names></name><name><surname>Lane</surname> <given-names>HC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Defective HIV-1 proviruses produce viral proteins</article-title><source>PNAS</source><volume>117</volume><fpage>3704</fpage><lpage>3710</lpage><pub-id pub-id-type="doi">10.1073/pnas.1917876117</pub-id><pub-id pub-id-type="pmid">32029589</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobs</surname> <given-names>JL</given-names></name><name><surname>Halvas</surname> <given-names>EK</given-names></name><name><surname>Tosiano</surname> <given-names>MA</given-names></name><name><surname>Mellors</surname> <given-names>JW</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Persistent HIV-1 viremia on antiretroviral therapy: measurement and mechanisms</article-title><source>Frontiers in Microbiology</source><volume>10</volume><elocation-id>2383</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2019.02383</pub-id><pub-id pub-id-type="pmid">31681237</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jochmans</surname> <given-names>D</given-names></name><name><surname>Anders</surname> <given-names>M</given-names></name><name><surname>Keuleers</surname> <given-names>I</given-names></name><name><surname>Smeulders</surname> <given-names>L</given-names></name><name><surname>Kräusslich</surname> <given-names>HG</given-names></name><name><surname>Kraus</surname> <given-names>G</given-names></name><name><surname>Müller</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Selective killing of human immunodeficiency virus infected cells by non-nucleoside reverse transcriptase inhibitor-induced activation of HIV protease</article-title><source>Retrovirology</source><volume>7</volume><elocation-id>89</elocation-id><pub-id pub-id-type="doi">10.1186/1742-4690-7-89</pub-id><pub-id pub-id-type="pmid">20950436</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joos</surname> <given-names>B</given-names></name><name><surname>Fischer</surname> <given-names>M</given-names></name><name><surname>Kuster</surname> <given-names>H</given-names></name><name><surname>Pillai</surname> <given-names>SK</given-names></name><name><surname>Wong</surname> <given-names>JK</given-names></name><name><surname>Böni</surname> <given-names>J</given-names></name><name><surname>Hirschel</surname> <given-names>B</given-names></name><name><surname>Weber</surname> <given-names>R</given-names></name><name><surname>Trkola</surname> <given-names>A</given-names></name><name><surname>Günthard</surname> <given-names>HF</given-names></name><collab>Swiss HIV Cohort Study</collab></person-group><year iso-8601-date="2008">2008</year><article-title>HIV rebounds from latently infected cells, rather than from continuing low-level replication</article-title><source>PNAS</source><volume>105</volume><fpage>16725</fpage><lpage>16730</lpage><pub-id pub-id-type="doi">10.1073/pnas.0804192105</pub-id><pub-id pub-id-type="pmid">18936487</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiselinova</surname> <given-names>M</given-names></name><name><surname>Geretti</surname> <given-names>AM</given-names></name><name><surname>Malatinkova</surname> <given-names>E</given-names></name><name><surname>Vervisch</surname> <given-names>K</given-names></name><name><surname>Beloukas</surname> <given-names>A</given-names></name><name><surname>Messiaen</surname> <given-names>P</given-names></name><name><surname>Bonczkowski</surname> <given-names>P</given-names></name><name><surname>Trypsteen</surname> <given-names>W</given-names></name><name><surname>Callens</surname> <given-names>S</given-names></name><name><surname>Verhofstede</surname> <given-names>C</given-names></name><name><surname>De Spiegelaere</surname> <given-names>W</given-names></name><name><surname>Vandekerckhove</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>HIV-1 RNA and HIV-1 DNA persistence during suppressive ART with PI-based or nevirapine-based regimens</article-title><source>Journal of Antimicrobial Chemotherapy</source><volume>3</volume><elocation-id>dkv250</elocation-id><pub-id pub-id-type="doi">10.1093/jac/dkv250</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klatt</surname> <given-names>NR</given-names></name><name><surname>Chomont</surname> <given-names>N</given-names></name><name><surname>Douek</surname> <given-names>DC</given-names></name><name><surname>Deeks</surname> <given-names>SG</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Immune activation and HIV persistence: implications for curative approaches to HIV infection</article-title><source>Immunological Reviews</source><volume>254</volume><fpage>326</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1111/imr.12065</pub-id><pub-id pub-id-type="pmid">23772629</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Konstantopoulos</surname> <given-names>C</given-names></name><name><surname>Ribaudo</surname> <given-names>H</given-names></name><name><surname>Ragland</surname> <given-names>K</given-names></name><name><surname>Bangsberg</surname> <given-names>DR</given-names></name><name><surname>Li</surname> <given-names>JZ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Antiretroviral regimen and suboptimal medication adherence are associated with low-level human immunodeficiency virus viremia</article-title><source>Open Forum Infectious Diseases</source><volume>2</volume><elocation-id>ofu119</elocation-id><pub-id pub-id-type="doi">10.1093/ofid/ofu119</pub-id><pub-id pub-id-type="pmid">25884007</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>JZ</given-names></name><name><surname>Etemad</surname> <given-names>B</given-names></name><name><surname>Ahmed</surname> <given-names>H</given-names></name><name><surname>Aga</surname> <given-names>E</given-names></name><name><surname>Bosch</surname> <given-names>RJ</given-names></name><name><surname>Mellors</surname> <given-names>JW</given-names></name><name><surname>Kuritzkes</surname> <given-names>DR</given-names></name><name><surname>Lederman</surname> <given-names>MM</given-names></name><name><surname>Para</surname> <given-names>M</given-names></name><name><surname>Gandhi</surname> <given-names>RT</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption</article-title><source>Aids</source><volume>30</volume><fpage>343</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000000953</pub-id><pub-id pub-id-type="pmid">26588174</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lohse</surname> <given-names>N</given-names></name><name><surname>Hansen</surname> <given-names>AB</given-names></name><name><surname>Pedersen</surname> <given-names>G</given-names></name><name><surname>Kronborg</surname> <given-names>G</given-names></name><name><surname>Gerstoft</surname> <given-names>J</given-names></name><name><surname>Sørensen</surname> <given-names>HT</given-names></name><name><surname>Vaeth</surname> <given-names>M</given-names></name><name><surname>Obel</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Survival of persons with and without HIV infection in Denmark, 1995-2005</article-title><source>Annals of Internal Medicine</source><volume>146</volume><fpage>87</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-146-2-200701160-00003</pub-id><pub-id pub-id-type="pmid">17227932</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lorenzo-Redondo</surname> <given-names>R</given-names></name><name><surname>Fryer</surname> <given-names>HR</given-names></name><name><surname>Bedford</surname> <given-names>T</given-names></name><name><surname>Kim</surname> <given-names>EY</given-names></name><name><surname>Archer</surname> <given-names>J</given-names></name><name><surname>Pond</surname> <given-names>SLK</given-names></name><name><surname>Chung</surname> <given-names>YS</given-names></name><name><surname>Penugonda</surname> <given-names>S</given-names></name><name><surname>Chipman</surname> <given-names>J</given-names></name><name><surname>Fletcher</surname> <given-names>CV</given-names></name><name><surname>Schacker</surname> <given-names>TW</given-names></name><name><surname>Malim</surname> <given-names>MH</given-names></name><name><surname>Rambaut</surname> <given-names>A</given-names></name><name><surname>Haase</surname> <given-names>AT</given-names></name><name><surname>McLean</surname> <given-names>AR</given-names></name><name><surname>Wolinsky</surname> <given-names>SM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Persistent HIV-1 replication maintains the tissue reservoir during therapy</article-title><source>Nature</source><volume>530</volume><fpage>51</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1038/nature16933</pub-id><pub-id pub-id-type="pmid">26814962</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maldarelli</surname> <given-names>F</given-names></name><name><surname>Wu</surname> <given-names>X</given-names></name><name><surname>Su</surname> <given-names>L</given-names></name><name><surname>Simonetti</surname> <given-names>FR</given-names></name><name><surname>Shao</surname> <given-names>W</given-names></name><name><surname>Hill</surname> <given-names>S</given-names></name><name><surname>Spindler</surname> <given-names>J</given-names></name><name><surname>Ferris</surname> <given-names>AL</given-names></name><name><surname>Mellors</surname> <given-names>JW</given-names></name><name><surname>Kearney</surname> <given-names>MF</given-names></name><name><surname>Coffin</surname> <given-names>JM</given-names></name><name><surname>Hughes</surname> <given-names>SH</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Specific HIV integration sites are linked to clonal expansion and persistence of infected cells</article-title><source>Science</source><volume>345</volume><fpage>179</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1126/science.1254194</pub-id><pub-id pub-id-type="pmid">24968937</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malnati</surname> <given-names>MS</given-names></name><name><surname>Scarlatti</surname> <given-names>G</given-names></name><name><surname>Gatto</surname> <given-names>F</given-names></name><name><surname>Salvatori</surname> <given-names>F</given-names></name><name><surname>Cassina</surname> <given-names>G</given-names></name><name><surname>Rutigliano</surname> <given-names>T</given-names></name><name><surname>Volpi</surname> <given-names>R</given-names></name><name><surname>Lusso</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>A universal real-time PCR assay for the quantification of group-M HIV-1 proviral load</article-title><source>Nature Protocols</source><volume>3</volume><fpage>1240</fpage><lpage>1248</lpage><pub-id pub-id-type="doi">10.1038/nprot.2008.108</pub-id><pub-id pub-id-type="pmid">18600229</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Picado</surname> <given-names>J</given-names></name><name><surname>Deeks</surname> <given-names>SG</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Persistent HIV-1 replication during antiretroviral therapy</article-title><source>Current Opinion in HIV and AIDS</source><volume>11</volume><fpage>417</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1097/COH.0000000000000287</pub-id><pub-id pub-id-type="pmid">27078619</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Massanella</surname> <given-names>M</given-names></name><name><surname>Fromentin</surname> <given-names>R</given-names></name><name><surname>Chomont</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Residual inflammation and viral reservoirs: alliance against an HIV cure</article-title><source>Current Opinion in HIV and AIDS</source><volume>11</volume><fpage>234</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1097/COH.0000000000000230</pub-id><pub-id pub-id-type="pmid">26575148</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McMahon</surname> <given-names>D</given-names></name><name><surname>Jones</surname> <given-names>J</given-names></name><name><surname>Wiegand</surname> <given-names>A</given-names></name><name><surname>Gange</surname> <given-names>SJ</given-names></name><name><surname>Kearney</surname> <given-names>M</given-names></name><name><surname>Palmer</surname> <given-names>S</given-names></name><name><surname>McNulty</surname> <given-names>S</given-names></name><name><surname>Metcalf</surname> <given-names>JA</given-names></name><name><surname>Acosta</surname> <given-names>E</given-names></name><name><surname>Rehm</surname> <given-names>C</given-names></name><name><surname>Coffin</surname> <given-names>JM</given-names></name><name><surname>Mellors</surname> <given-names>JW</given-names></name><name><surname>Maldarelli</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy</article-title><source>Clinical Infectious Diseases</source><volume>50</volume><fpage>912</fpage><lpage>919</lpage><pub-id pub-id-type="doi">10.1086/650749</pub-id><pub-id pub-id-type="pmid">20156060</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicastri</surname> <given-names>E</given-names></name><name><surname>Palmisano</surname> <given-names>L</given-names></name><name><surname>Sarmati</surname> <given-names>L</given-names></name><name><surname>D'Ettorre</surname> <given-names>G</given-names></name><name><surname>Parisi</surname> <given-names>S</given-names></name><name><surname>Andreotti</surname> <given-names>M</given-names></name><name><surname>Buonomini</surname> <given-names>A</given-names></name><name><surname>Pirillo</surname> <given-names>FM</given-names></name><name><surname>Narciso</surname> <given-names>P</given-names></name><name><surname>Bellagamba</surname> <given-names>R</given-names></name><name><surname>Vullo</surname> <given-names>V</given-names></name><name><surname>Montano</surname> <given-names>M</given-names></name><name><surname>Di Perri</surname> <given-names>G</given-names></name><name><surname>Andreoni</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>HIV-1 residual viremia and proviral DNA in patients with suppressed plasma viral load (&lt;400 HIV-RNA cp/ml) during different antiretroviral regimens</article-title><source>Current HIV Research</source><volume>6</volume><fpage>261</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.2174/157016208784325010</pub-id><pub-id pub-id-type="pmid">18473790</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Connor</surname> <given-names>JL</given-names></name><name><surname>Gardner</surname> <given-names>EM</given-names></name><name><surname>Mannheimer</surname> <given-names>SB</given-names></name><name><surname>Lifson</surname> <given-names>AR</given-names></name><name><surname>Esser</surname> <given-names>S</given-names></name><name><surname>Telzak</surname> <given-names>EE</given-names></name><name><surname>Phillips</surname> <given-names>AN</given-names></name><collab>INSIGHT SMART Study Group</collab></person-group><year iso-8601-date="2013">2013</year><article-title>Factors associated with adherence amongst 5295 people receiving antiretroviral therapy as part of an international trial</article-title><source>The Journal of Infectious Diseases</source><volume>208</volume><fpage>40</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1093/infdis/jis731</pub-id><pub-id pub-id-type="pmid">23204161</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palmer</surname> <given-names>S</given-names></name><name><surname>Maldarelli</surname> <given-names>F</given-names></name><name><surname>Wiegand</surname> <given-names>A</given-names></name><name><surname>Bernstein</surname> <given-names>B</given-names></name><name><surname>Hanna</surname> <given-names>GJ</given-names></name><name><surname>Brun</surname> <given-names>SC</given-names></name><name><surname>Kempf</surname> <given-names>DJ</given-names></name><name><surname>Mellors</surname> <given-names>JW</given-names></name><name><surname>Coffin</surname> <given-names>JM</given-names></name><name><surname>King</surname> <given-names>MS</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy</article-title><source>PNAS</source><volume>105</volume><fpage>3879</fpage><lpage>3884</lpage><pub-id pub-id-type="doi">10.1073/pnas.0800050105</pub-id><pub-id pub-id-type="pmid">18332425</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pankau</surname> <given-names>MD</given-names></name><name><surname>Reeves</surname> <given-names>DB</given-names></name><name><surname>Harkins</surname> <given-names>E</given-names></name><name><surname>Ronen</surname> <given-names>K</given-names></name><name><surname>Jaoko</surname> <given-names>W</given-names></name><name><surname>Mandaliya</surname> <given-names>K</given-names></name><name><surname>Graham</surname> <given-names>SM</given-names></name><name><surname>McClelland</surname> <given-names>RS</given-names></name><name><surname>Matsen Iv</surname> <given-names>FA</given-names></name><name><surname>Schiffer</surname> <given-names>JT</given-names></name><name><surname>Overbaugh</surname> <given-names>J</given-names></name><name><surname>Lehman</surname> <given-names>DA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Dynamics of HIV DNA reservoir seeding in a cohort of superinfected kenyan women</article-title><source>PLOS Pathogens</source><volume>16</volume><elocation-id>e1008286</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1008286</pub-id><pub-id pub-id-type="pmid">32023326</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pardons</surname> <given-names>M</given-names></name><name><surname>Baxter</surname> <given-names>AE</given-names></name><name><surname>Massanella</surname> <given-names>M</given-names></name><name><surname>Pagliuzza</surname> <given-names>A</given-names></name><name><surname>Fromentin</surname> <given-names>R</given-names></name><name><surname>Dufour</surname> <given-names>C</given-names></name><name><surname>Leyre</surname> <given-names>L</given-names></name><name><surname>Routy</surname> <given-names>JP</given-names></name><name><surname>Kaufmann</surname> <given-names>DE</given-names></name><name><surname>Chomont</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Single-cell characterization and quantification of translation-competent viral reservoirs in treated and untreated HIV infection</article-title><source>PLOS Pathogens</source><volume>15</volume><elocation-id>e1007619</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1007619</pub-id><pub-id pub-id-type="pmid">30811499</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasternak</surname> <given-names>AO</given-names></name><name><surname>Adema</surname> <given-names>KW</given-names></name><name><surname>Bakker</surname> <given-names>M</given-names></name><name><surname>Jurriaans</surname> <given-names>S</given-names></name><name><surname>Berkhout</surname> <given-names>B</given-names></name><name><surname>Cornelissen</surname> <given-names>M</given-names></name><name><surname>Lukashov</surname> <given-names>VV</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Highly sensitive methods based on seminested real-time reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 unspliced and multiply spliced RNA and proviral DNA</article-title><source>Journal of Clinical Microbiology</source><volume>46</volume><fpage>2206</fpage><lpage>2211</lpage><pub-id pub-id-type="doi">10.1128/JCM.00055-08</pub-id><pub-id pub-id-type="pmid">18463204</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasternak</surname> <given-names>AO</given-names></name><name><surname>Jurriaans</surname> <given-names>S</given-names></name><name><surname>Bakker</surname> <given-names>M</given-names></name><name><surname>Prins</surname> <given-names>JM</given-names></name><name><surname>Berkhout</surname> <given-names>B</given-names></name><name><surname>Lukashov</surname> <given-names>VV</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome</article-title><source>PLOS ONE</source><volume>4</volume><elocation-id>e8490</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0008490</pub-id><pub-id pub-id-type="pmid">20046870</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasternak</surname> <given-names>AO</given-names></name><name><surname>de Bruin</surname> <given-names>M</given-names></name><name><surname>Jurriaans</surname> <given-names>S</given-names></name><name><surname>Bakker</surname> <given-names>M</given-names></name><name><surname>Berkhout</surname> <given-names>B</given-names></name><name><surname>Prins</surname> <given-names>JM</given-names></name><name><surname>Lukashov</surname> <given-names>VV</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Modest nonadherence to antiretroviral therapy promotes residual HIV-1 replication in the absence of virological rebound in plasma</article-title><source>The Journal of Infectious Diseases</source><volume>206</volume><fpage>1443</fpage><lpage>1452</lpage><pub-id pub-id-type="doi">10.1093/infdis/jis502</pub-id><pub-id pub-id-type="pmid">22927449</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasternak</surname> <given-names>AO</given-names></name><name><surname>Lukashov</surname> <given-names>VV</given-names></name><name><surname>Berkhout</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Cell-associated HIV RNA: a dynamic biomarker of viral persistence</article-title><source>Retrovirology</source><volume>10</volume><elocation-id>41</elocation-id><pub-id pub-id-type="doi">10.1186/1742-4690-10-41</pub-id><pub-id pub-id-type="pmid">23587031</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasternak</surname> <given-names>AO</given-names></name><name><surname>de Bruin</surname> <given-names>M</given-names></name><name><surname>Bakker</surname> <given-names>M</given-names></name><name><surname>Berkhout</surname> <given-names>B</given-names></name><name><surname>Prins</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>High current CD4+ T cell count predicts suboptimal adherence to antiretroviral therapy</article-title><source>PLOS ONE</source><volume>10</volume><elocation-id>e0140791</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0140791</pub-id><pub-id pub-id-type="pmid">26468956</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasternak</surname> <given-names>AO</given-names></name><name><surname>Grijsen</surname> <given-names>ML</given-names></name><name><surname>Wit</surname> <given-names>FW</given-names></name><name><surname>Bakker</surname> <given-names>M</given-names></name><name><surname>Jurriaans</surname> <given-names>S</given-names></name><name><surname>Prins</surname> <given-names>JM</given-names></name><name><surname>Berkhout</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cell-associated HIV-1 RNA predicts viral rebound and disease progression after discontinuation of temporary early ART</article-title><source>JCI Insight</source><volume>5</volume><elocation-id>e134196</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.134196</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasternak</surname> <given-names>AO</given-names></name><name><surname>Berkhout</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>HIV reservoir: finding the right needles in a needlestack</article-title><source>Cell Host &amp; Microbe</source><volume>20</volume><fpage>280</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2016.08.011</pub-id><pub-id pub-id-type="pmid">27631698</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasternak</surname> <given-names>AO</given-names></name><name><surname>Berkhout</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>What do we measure when we measure cell-associated HIV RNA</article-title><source>Retrovirology</source><volume>15</volume><elocation-id>13</elocation-id><pub-id pub-id-type="doi">10.1186/s12977-018-0397-2</pub-id><pub-id pub-id-type="pmid">29378657</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pau</surname> <given-names>AK</given-names></name><name><surname>George</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Antiretroviral therapy: current drugs</article-title><source>Infectious Disease Clinics of North America</source><volume>28</volume><fpage>371</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1016/j.idc.2014.06.001</pub-id><pub-id pub-id-type="pmid">25151562</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perelson</surname> <given-names>AS</given-names></name><name><surname>Essunger</surname> <given-names>P</given-names></name><name><surname>Cao</surname> <given-names>Y</given-names></name><name><surname>Vesanen</surname> <given-names>M</given-names></name><name><surname>Hurley</surname> <given-names>A</given-names></name><name><surname>Saksela</surname> <given-names>K</given-names></name><name><surname>Markowitz</surname> <given-names>M</given-names></name><name><surname>Ho</surname> <given-names>DD</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Decay characteristics of HIV-1-infected compartments during combination therapy</article-title><source>Nature</source><volume>387</volume><fpage>188</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1038/387188a0</pub-id><pub-id pub-id-type="pmid">9144290</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pollack</surname> <given-names>RA</given-names></name><name><surname>Jones</surname> <given-names>RB</given-names></name><name><surname>Pertea</surname> <given-names>M</given-names></name><name><surname>Bruner</surname> <given-names>KM</given-names></name><name><surname>Martin</surname> <given-names>AR</given-names></name><name><surname>Thomas</surname> <given-names>AS</given-names></name><name><surname>Capoferri</surname> <given-names>AA</given-names></name><name><surname>Beg</surname> <given-names>SA</given-names></name><name><surname>Huang</surname> <given-names>SH</given-names></name><name><surname>Karandish</surname> <given-names>S</given-names></name><name><surname>Hao</surname> <given-names>H</given-names></name><name><surname>Halper-Stromberg</surname> <given-names>E</given-names></name><name><surname>Yong</surname> <given-names>PC</given-names></name><name><surname>Kovacs</surname> <given-names>C</given-names></name><name><surname>Benko</surname> <given-names>E</given-names></name><name><surname>Siliciano</surname> <given-names>RF</given-names></name><name><surname>Ho</surname> <given-names>YC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Defective HIV-1 proviruses are expressed and can be recognized by cytotoxic T lymphocytes, which shape the proviral landscape</article-title><source>Cell Host &amp; Microbe</source><volume>21</volume><fpage>494</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2017.03.008</pub-id><pub-id pub-id-type="pmid">28407485</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarmati</surname> <given-names>L</given-names></name><name><surname>Parisi</surname> <given-names>SG</given-names></name><name><surname>Montano</surname> <given-names>M</given-names></name><name><surname>Andreis</surname> <given-names>S</given-names></name><name><surname>Scaggiante</surname> <given-names>R</given-names></name><name><surname>Galgani</surname> <given-names>A</given-names></name><name><surname>Viscione</surname> <given-names>M</given-names></name><name><surname>Maffongelli</surname> <given-names>G</given-names></name><name><surname>Ricciardi</surname> <given-names>A</given-names></name><name><surname>Andreoni</surname> <given-names>C</given-names></name><name><surname>Boros</surname> <given-names>S</given-names></name><name><surname>Palù</surname> <given-names>G</given-names></name><name><surname>Andreoni</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Nevirapine use, prolonged antiretroviral therapy and high CD4 nadir values are strongly correlated with undetectable HIV-DNA and -RNA levels and CD4 cell gain</article-title><source>Journal of Antimicrobial Chemotherapy</source><volume>67</volume><fpage>2932</fpage><lpage>2938</lpage><pub-id pub-id-type="doi">10.1093/jac/dks331</pub-id><pub-id pub-id-type="pmid">22915460</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schouten</surname> <given-names>J</given-names></name><name><surname>Wit</surname> <given-names>FW</given-names></name><name><surname>Stolte</surname> <given-names>IG</given-names></name><name><surname>Kootstra</surname> <given-names>NA</given-names></name><name><surname>van der Valk</surname> <given-names>M</given-names></name><name><surname>Geerlings</surname> <given-names>SE</given-names></name><name><surname>Prins</surname> <given-names>M</given-names></name><name><surname>Reiss</surname> <given-names>P</given-names></name><collab>AGEhIV Cohort Study Group</collab></person-group><year iso-8601-date="2014">2014</year><article-title>Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study</article-title><source>Clinical Infectious Diseases</source><volume>59</volume><fpage>1787</fpage><lpage>1797</lpage><pub-id pub-id-type="doi">10.1093/cid/ciu701</pub-id><pub-id pub-id-type="pmid">25182245</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharaf</surname> <given-names>RR</given-names></name><name><surname>Li</surname> <given-names>JZ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The alphabet soup of HIV reservoir markers</article-title><source>Current HIV/AIDS Reports</source><volume>14</volume><fpage>72</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1007/s11904-017-0355-y</pub-id><pub-id pub-id-type="pmid">28401492</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sigal</surname> <given-names>A</given-names></name><name><surname>Kim</surname> <given-names>JT</given-names></name><name><surname>Balazs</surname> <given-names>AB</given-names></name><name><surname>Dekel</surname> <given-names>E</given-names></name><name><surname>Mayo</surname> <given-names>A</given-names></name><name><surname>Milo</surname> <given-names>R</given-names></name><name><surname>Baltimore</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy</article-title><source>Nature</source><volume>477</volume><fpage>95</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1038/nature10347</pub-id><pub-id pub-id-type="pmid">21849975</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siliciano</surname> <given-names>JD</given-names></name><name><surname>Kajdas</surname> <given-names>J</given-names></name><name><surname>Finzi</surname> <given-names>D</given-names></name><name><surname>Quinn</surname> <given-names>TC</given-names></name><name><surname>Chadwick</surname> <given-names>K</given-names></name><name><surname>Margolick</surname> <given-names>JB</given-names></name><name><surname>Kovacs</surname> <given-names>C</given-names></name><name><surname>Gange</surname> <given-names>SJ</given-names></name><name><surname>Siliciano</surname> <given-names>RF</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells</article-title><source>Nature Medicine</source><volume>9</volume><fpage>727</fpage><lpage>728</lpage><pub-id pub-id-type="doi">10.1038/nm880</pub-id><pub-id pub-id-type="pmid">12754504</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trinité</surname> <given-names>B</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Levy</surname> <given-names>DN</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>NNRTI-induced HIV-1 protease-mediated cytotoxicity induces rapid death of CD4 T cells during productive infection and latency reversal</article-title><source>Retrovirology</source><volume>16</volume><elocation-id>17</elocation-id><pub-id pub-id-type="doi">10.1186/s12977-019-0479-9</pub-id><pub-id pub-id-type="pmid">31242909</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Zyl</surname> <given-names>GU</given-names></name><name><surname>Katusiime</surname> <given-names>MG</given-names></name><name><surname>Wiegand</surname> <given-names>A</given-names></name><name><surname>McManus</surname> <given-names>WR</given-names></name><name><surname>Bale</surname> <given-names>MJ</given-names></name><name><surname>Halvas</surname> <given-names>EK</given-names></name><name><surname>Luke</surname> <given-names>B</given-names></name><name><surname>Boltz</surname> <given-names>VF</given-names></name><name><surname>Spindler</surname> <given-names>J</given-names></name><name><surname>Laughton</surname> <given-names>B</given-names></name><name><surname>Engelbrecht</surname> <given-names>S</given-names></name><name><surname>Coffin</surname> <given-names>JM</given-names></name><name><surname>Cotton</surname> <given-names>MF</given-names></name><name><surname>Shao</surname> <given-names>W</given-names></name><name><surname>Mellors</surname> <given-names>JW</given-names></name><name><surname>Kearney</surname> <given-names>MF</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>No evidence of HIV replication in children on antiretroviral therapy</article-title><source>Journal of Clinical Investigation</source><volume>127</volume><fpage>3827</fpage><lpage>3834</lpage><pub-id pub-id-type="doi">10.1172/JCI94582</pub-id><pub-id pub-id-type="pmid">28891813</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname> <given-names>TA</given-names></name><name><surname>McLaughlin</surname> <given-names>S</given-names></name><name><surname>Garg</surname> <given-names>K</given-names></name><name><surname>Cheung</surname> <given-names>CY</given-names></name><name><surname>Larsen</surname> <given-names>BB</given-names></name><name><surname>Styrchak</surname> <given-names>S</given-names></name><name><surname>Huang</surname> <given-names>HC</given-names></name><name><surname>Edlefsen</surname> <given-names>PT</given-names></name><name><surname>Mullins</surname> <given-names>JI</given-names></name><name><surname>Frenkel</surname> <given-names>LM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Proliferation of cells with HIV integrated into Cancer genes contributes to persistent infection</article-title><source>Science</source><volume>345</volume><fpage>570</fpage><lpage>573</lpage><pub-id pub-id-type="doi">10.1126/science.1256304</pub-id><pub-id pub-id-type="pmid">25011556</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>Q</given-names></name><name><surname>Gao</surname> <given-names>H</given-names></name><name><surname>Clark</surname> <given-names>KM</given-names></name><name><surname>Mugisha</surname> <given-names>CS</given-names></name><name><surname>Davis</surname> <given-names>K</given-names></name><name><surname>Tang</surname> <given-names>JP</given-names></name><name><surname>Harlan</surname> <given-names>GH</given-names></name><name><surname>DeSelm</surname> <given-names>CJ</given-names></name><name><surname>Presti</surname> <given-names>RM</given-names></name><name><surname>Kutluay</surname> <given-names>SB</given-names></name><name><surname>Shan</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>CARD8 is an inflammasome sensor for HIV-1 protease activity</article-title><source>Science</source><volume>371</volume><elocation-id>eabe1707</elocation-id><pub-id pub-id-type="doi">10.1126/science.abe1707</pub-id><pub-id pub-id-type="pmid">33542150</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname> <given-names>JP</given-names></name><name><surname>Hurst</surname> <given-names>J</given-names></name><name><surname>Stöhr</surname> <given-names>W</given-names></name><name><surname>Robinson</surname> <given-names>N</given-names></name><name><surname>Brown</surname> <given-names>H</given-names></name><name><surname>Fisher</surname> <given-names>M</given-names></name><name><surname>Kinloch</surname> <given-names>S</given-names></name><name><surname>Cooper</surname> <given-names>D</given-names></name><name><surname>Schechter</surname> <given-names>M</given-names></name><name><surname>Tambussi</surname> <given-names>G</given-names></name><name><surname>Fidler</surname> <given-names>S</given-names></name><name><surname>Carrington</surname> <given-names>M</given-names></name><name><surname>Babiker</surname> <given-names>A</given-names></name><name><surname>Weber</surname> <given-names>J</given-names></name><name><surname>Koelsch</surname> <given-names>KK</given-names></name><name><surname>Kelleher</surname> <given-names>AD</given-names></name><name><surname>Phillips</surname> <given-names>RE</given-names></name><name><surname>Frater</surname> <given-names>J</given-names></name><collab>SPARTACTrial Investigators</collab></person-group><year iso-8601-date="2014">2014</year><article-title>HIV-1 DNA predicts disease progression and post-treatment virological control</article-title><source>eLife</source><volume>3</volume><elocation-id>e03821</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.03821</pub-id><pub-id pub-id-type="pmid">25217531</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.68174.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Overbaugh</surname><given-names>Julie M</given-names></name><role>Reviewing Editor</role><aff><institution>Fred Hutchinson Cancer Research Center</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Van der Meer</surname><given-names>Jos W</given-names></name><role>Reviewer</role><aff><institution>Fred Hutchinson Cancer Research Center</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>Our editorial process produces two outputs: i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2021.03.25.21254129">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.medrxiv.org/content/10.1101/2021.03.25.21254129v1">the preprint</ext-link> for the benefit of readers; ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>This study examines measures of the HIV reservoir in two cohorts treated with different ART regimens. The findings indicate that the HIV reservoir is lower in virally suppressed individuals on NNRTI-based than PI-based regimens. This was observed in both cohorts, further supporting this finding.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Non-nucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy is associated with lower cell-associated HIV RNA and DNA levels as compared with therapy based on protease inhibitors&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, including Julie M Overbaugh as the Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Jos van der Meer as the Senior Editor.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>This is a well-written study that will be of interest to many investigators working in the field of HIV persistence during ART. The strengths of the study include the analysis of samples from two relatively large cohorts of individuals (n = 100 and 124) and the use of multivariable models to adjust for numerous parameters. One weakness is the fact that the authors do not consider alternative models that may explain their results. This includes the interaction between viral reservoir and longer viral suppression, both of which were associated with NNRTI-based regimens. The data is important and shows that NNRTI usage is associated with lower levels of HIV persistence markers, but it does not provide a mechanistic explanation for that. Overall, this is a well-conducted and important study, with new findings that have potential clinical implications.</p><p>1) A main concern is the interaction between duration of viral suppression and the reservoir given the reservoir decays with time. This could contribute to the results and appears to do so for the AIMs cohort; it feels like it is a bit of a chicken and egg issue with this which probably should be discussed more in terms of limitations. The authors do one analysis where they restrict the cases to those with more the 6 months of viral suppression to try to get at the impact of suppression. But I think this would be more telling if they did an analysis around intervals of suppression (6 months to 1 year, 1 year to 2 years etc) as the analysis they did still could be driven by the long duration of some individuals and the associated decay due to that.</p><p>2) At the end of the abstract and in a large part of the discussion, the authors propose that their results are explained by the fact that NNRTI have a greater ability to suppress HIV replication. There are alternative explanations: It may be that people on NNRTI clear their transcriptionally active reservoir continuously: The authors should discuss their findings in connection with the recent study by the group of Dr Shan (Lang et al. Nature 2021). In this study, the authors demonstrated that the use of NNRTI may lead to the clearance of transcriptionally active HIV-infected cells through autophagy. Interestingly, the use of PI would block this phenomenon. Lang et al. found that both efavirenz and rilpivirine can lead to the death of transcriptionally active HIV-infected cells, whereas nevirapine has no effect (because it does not enhance dimerization of the gag-pol polyprotein intracellularly). Although this contrasts with the results of the present study, this should be extensively discussed. Also, although the number of participants receiving rilpivirine is probably small, they may be included Figure 3C.</p><p>3) The authors should perform a more exhaustive review of the literature in the introduction by quoting the studies that have compared the effects of different ART regimens on HIV DNA and cell-associated HIV RNA levels. See for example Nicastri et al., Curr HIV Res 2008. Some of these studies are included in the discussion, but there are probably many more that should be included in the introduction (including comparisons with integrase inhibitors). I suggest to briefly review these studies after the sentence &quot;However, to date, few studies have compared levels of CA HIV reservoir markers between different ART regimens&quot;.</p><p>4) Table 1 shows that in the COBRA cohort, the participants on PI regimens have a shorter duration of continuous viral suppression compared to those taking NNRTI. This is likely an important bias here and although the adjusted analysis shows that the differences between the two groups persist after adjusting for this parameter, this should be discussed (page 6 when these differences are presented, not only in the discussion). Same remark for the AIMS cohort.</p><p>5) In all correlations, it would be nice to represent the participants PI VS NNRTI using two different colors. This will help the reader determining whether these two groups from separate clusters in all these associations.</p><p>6) The differences between Figure 3 A and 3B should be visible in the figure (add a title/label at the top of the graphs or change the Y axis label).</p><p>7) Figure 3 C (and D) should be modified: The authors compared each NNRTI (EFV or NVP to all PI in A and B) but each PI to the other PIs only (no comparison with NNRTI). It would be much simpler to redraw this figure and represent all drugs individually (PIs and NNRTIs) and use multiple comparisons.</p><p>8) Have the authors attempted to calculate the HIV RNA/HIV DNA ratio in both groups? This would be a better indicator of the viral transcriptional activity.</p><p>9) The authors should discuss the need for a clinical trial in which participants would switch from PI to NNRTI to definitely confirm their findings in a longitudinal way.</p><p>10) in one of their study cohorts, the authors do not observe an association between duration of ART and cell-associated HIV DNA/RNA levels; this could be due to clonal expansion of viral reservoir cells that amplify and expand viral reservoir size during long-term ART. The authors may wish to discuss this.</p><p>11) the authors cite Li et al. (ref 60) to argue that NNRTI treatment is associated with delayed viral rebound after treatment interruption; however, this is likely unrelated to viral reservoir size, and rather caused by altered PK and the longer half-life of NNRTIS relative to PIs.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.68174.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>This is a well-written study that will be of interest to many investigators working in the field of HIV persistence during ART. The strengths of the study include the analysis of samples from two relatively large cohorts of individuals (n = 100 and 124) and the use of multivariable models to adjust for numerous parameters. One weakness is the fact that the authors do not consider alternative models that may explain their results. This includes the interaction between viral reservoir and longer viral suppression, both of which were associated with NNRTI-based regimens. The data is important and shows that NNRTI usage is associated with lower levels of HIV persistence markers, but it does not provide a mechanistic explanation for that. Overall, this is a well-conducted and important study, with new findings that have potential clinical implications.</p></disp-quote><p>We thank the Editor and the Reviewers for their positive assessment of our study. We now included a discussion of possible alternative explanations of our results (see response to comment 2) and an additional figure showing that the differences in CA RNA and DNA between NNRTI- and PI-treated individuals are independent of the duration of suppression (see response to comments 1 and 4).</p><disp-quote content-type="editor-comment"><p>1) A main concern is the interaction between duration of viral suppression and the reservoir given the reservoir decays with time. This could contribute to the results and appears to do so for the AIMs cohort; it feels like it is a bit of a chicken and egg issue with this which probably should be discussed more in terms of limitations. The authors do one analysis where they restrict the cases to those with more the 6 months of viral suppression to try to get at the impact of suppression. But I think this would be more telling if they did an analysis around intervals of suppression (6 months to 1 year, 1 year to 2 years etc) as the analysis they did still could be driven by the long duration of some individuals and the associated decay due to that.</p></disp-quote><p>We understand the concerns of the reviewer and feel several points need to be clarified. First, the duration of suppression could have potentially confounded the association of the ART regimen with CA RNA and DNA only in the AIMS cohort but not in the COBRA cohort, because only in the AIMS cohort the duration of suppression was associated with CA RNA and DNA. We extensively discuss this finding, as well as possible reasons behind it, in the Discussion. Second, to exclude this potential confounding, we performed multivariable analysis, adjusting for the duration of suppression and other variables, and found an independent association of the ART regimen with CA RNA and DNA in both cohorts. We even built three alternative models for the AIMS cohort, which did not change the results. Therefore, the duration of suppression does not confound the association of the ART regimen with CA RNA and DNA. To illustrate this further, we now performed the analysis suggested by the reviewer, assigning the participants into four groups according to the duration of suppression (Figure 3—figure supplement 2), and comparing CA RNA and DNA between NNRTI- and PI-treated individuals in every group separately. In every of the four groups, CA RNA levels were lower in NNRTI- then in PI-treated participants, with a similar but weaker effect observed for CA DNA, in a complete agreement to the results obtained in the total cohort. This is an additional demonstration that the duration of suppression is not a confounding factor in our analysis.</p><disp-quote content-type="editor-comment"><p>2) At the end of the abstract and in a large part of the discussion, the authors propose that their results are explained by the fact that NNRTI have a greater ability to suppress HIV replication. There are alternative explanations: It may be that people on NNRTI clear their transcriptionally active reservoir continuously: The authors should discuss their findings in connection with the recent study by the group of Dr Shan (Lang et al. Nature 2021). In this study, the authors demonstrated that the use of NNRTI may lead to the clearance of transcriptionally active HIV-infected cells through autophagy. Interestingly, the use of PI would block this phenomenon. Lang et al. found that both efavirenz and rilpivirine can lead to the death of transcriptionally active HIV-infected cells, whereas nevirapine has no effect (because it does not enhance dimerization of the gag-pol polyprotein intracellularly). Although this contrasts with the results of the present study, this should be extensively discussed. Also, although the number of participants receiving rilpivirine is probably small, they may be included Figure 3C.</p></disp-quote><p>The reviewer is referring to the recent paper of Wang et al. (Science 2021; 371:1224). Their findings concerning this NNRTI action are not new, several groups studied this in the past (Trinité Retrovirology 2019, Figueiredo PLOS Pathog 2006, Jochmans Retrovirology 2010, Zerbato Antimicrob Agents Chemother 2017). In essence, some NNRTIs, such as rilpivirine, efavirenz, and etravirine, but not nevirapine, can promote selective apoptosis of infected cells by inducing HIV protease-mediated cytotoxicity. If these NNRTIs are present in cells that are actively producing viral proteins, they may bind to the reverse transcriptase portion of a newly translated Gag-Pol polyprotein and promote its homodimerization, resulting in premature protease activation. This leads to a decrease in virus production and non-specific cleavage of multiple host proteins, including proteins that induce apoptosis/pyroptosis (and, as Wang et al. now show, CARD8 inflammasome activation).</p><p>However, we think this alternative explanation for the effects of NNRTIs on CA RNA and DNA that we see in our cohorts is very unlikely, for two reasons. First, for this mechanism to work, a cell has to express HIV Gag-Pol, and cells that express HIV proteins without ex vivo stimulation are exceedingly rare in ART-treated individuals. In fact, Pardons et al. (Plos Pathogens 2019) could not find any Gag-expressing cell in any of their patients unless they reversed latency ex vivo. Second, nevirapine, in comparison with other NNRTIs, has absolutely no such activity – and in our study, nevirapine was associated with the same levels of CA RNA and DNA as efavirenz (Figure 3C). In fact, some studies showed even lower levels of residual plasma viremia in nevirapine-treated compared to efavirenz-treated patients (Haim-Boukobza AIDS 2011), which might be because nevirapine better penetrates some anatomical sanctuaries. Therefore, this mechanism cannot really explain our findings. We discuss this in the revised manuscript (pages 20-21). We did not include rilpivirine in Figure 3C because there were only 2 participants treated with this drug in our study, which is insufficient to draw any conclusions about the effects of this drug.</p><disp-quote content-type="editor-comment"><p>3) The authors should perform a more exhaustive review of the literature in the introduction by quoting the studies that have compared the effects of different ART regimens on HIV DNA and cell-associated HIV RNA levels. See for example Nicastri et al., Curr HIV Res 2008. Some of these studies are included in the discussion, but there are probably many more that should be included in the introduction (including comparisons with integrase inhibitors). I suggest to briefly review these studies after the sentence &quot;However, to date, few studies have compared levels of CA HIV reservoir markers between different ART regimens&quot;.</p></disp-quote><p>We would like to draw the reviewer’s attention to our recent review published in Viruses (Darcis et al., Viruses 2020; 12, 489), where we extensively review the available evidence on differences in HIV markers between infected individuals treated with different ART regimens. We performed a very rigorous literature search for this review (see Table 1 in the review). This review is cited in the present manuscript (ref. 28). The absolute majority of such studies measured only residual plasma viremia and only a very few studies measured cell-associated HIV markers: we discuss these studies in the Discussion (including the paper of Nicastri et al. the reviewer is referring to) but we followed the suggestion of the reviewer and now refer to them in the Introduction as well (refs. 29-31).</p><disp-quote content-type="editor-comment"><p>4) Table 1 shows that in the COBRA cohort, the participants on PI regimens have a shorter duration of continuous viral suppression compared to those taking NNRTI. This is likely an important bias here and although the adjusted analysis shows that the differences between the two groups persist after adjusting for this parameter, this should be discussed (page 6 when these differences are presented, not only in the discussion). Same remark for the AIMS cohort.</p></disp-quote><p>Please see the response to the comment 1. Yes, in both cohorts the duration of suppression was lower in PI-treated than in NNRTI-treated participants, but in the COBRA cohort this effect could not even potentially have confounded the association of the ART regimen with CA RNA and DNA, because the duration of suppression was not associated with CA RNA and DNA in this cohort. Such potential confounding could have occurred in the AIMS cohort and we performed an extensive multivariable analysis to rule it out. Moreover, we now performed an additional analysis, in which participants were grouped according to the duration of suppression (Figure 3—figure supplement 2). Combined, our results show that CA RNA and DNA are associated with the ART regimen independently of the duration of suppression.</p><disp-quote content-type="editor-comment"><p>5) In all correlations, it would be nice to represent the participants PI VS NNRTI using two different colors. This will help the reader determining whether these two groups from separate clusters in all these associations.</p></disp-quote><p>We thank the reviewer for this suggestion, which we followed. Figure 1 now shows NNRTI- and PI-treated participants in different colors.</p><disp-quote content-type="editor-comment"><p>6) The differences between Figure 3 A and 3B should be visible in the figure (add a title/label at the top of the graphs or change the Y axis label).</p></disp-quote><p>Thank you, titles added on top of the graphs.</p><disp-quote content-type="editor-comment"><p>7) Figure 3 C (and D) should be modified: The authors compared each NNRTI (EFV or NVP to all PI in A and B) but each PI to the other PIs only (no comparison with NNRTI). It would be much simpler to redraw this figure and represent all drugs individually (PIs and NNRTIs) and use multiple comparisons.</p></disp-quote><p>Representing all drugs individually results in comparing too many groups with very unequal sizes (e.g. 68 participants were treated with efavirenz but only 12 with lopinavir), which considerably reduces the statistical power. In addition, we wanted to check whether both EFV and NVP are associated with lower CA RNA levels compared to PIs (and whether there is a difference between EFV and NVP), to rule out the alternative explanation for our results (see comment 2). Therefore, in figure 3C we compare EFV, NVP, and PIs, and in figure 3D we compare different PIs between each other. We think this comparison is more informative, and the results suggest that the effects of ART regimens on the CA RNA and DNA levels are ART class-specific and not drug-specific. However, we now also included the multiple comparisons suggested by the reviewer (Figure 3—figure supplement 3).</p><disp-quote content-type="editor-comment"><p>8) Have the authors attempted to calculate the HIV RNA/HIV DNA ratio in both groups? This would be a better indicator of the viral transcriptional activity.</p></disp-quote><p>We thank the reviewer for this suggestion and now included the comparison of CA RNA/DNA ratios between NNRTI- and PI-treated participants (Figure 3—figure supplement 1). Although there was a trend towards lower CA RNA/DNA ratios in NNRTI-treated participants, the difference was not significant (p=0.19), which is in line with the observations that both CA RNA and DNA levels were significantly lower in NNRTI-treated participants (p=0.0006 and p=0.01, respectively; Figure 3A).</p><disp-quote content-type="editor-comment"><p>9) The authors should discuss the need for a clinical trial in which participants would switch from PI to NNRTI to definitely confirm their findings in a longitudinal way.</p></disp-quote><p>This is added to the Discussion (page 23).</p><disp-quote content-type="editor-comment"><p>10) in one of their study cohorts, the authors do not observe an association between duration of ART and cell-associated HIV DNA/RNA levels; this could be due to clonal expansion of viral reservoir cells that amplify and expand viral reservoir size during long-term ART. The authors may wish to discuss this.</p></disp-quote><p>This is a nice suggestion. We did discuss that the lack of association between duration of suppression and CA RNA and DNA in the COBRA cohort is probably due to the fact that after several years on ART, CA RNA and DNA reach a plateau and do not decline further. The reviewer provides a plausible explanation for this plateau effect. We agree and have included this in the Discussion (page 18).</p><disp-quote content-type="editor-comment"><p>11) the authors cite Li et al. (ref 60) to argue that NNRTI treatment is associated with delayed viral rebound after treatment interruption; however, this is likely unrelated to viral reservoir size, and rather caused by altered PK and the longer half-life of NNRTIS relative to PIs.</p></disp-quote><p>We agree that this could contribute to the results of Li et al. and included this in the Discussion (page 22).</p></body></sub-article></article>